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Foreword 
My interest in drug use among pregnant women was born when I was doing my master’s 
degree in social pharmacy and collected data at the maternity ward at Haukeland 
University Hospital. My master’s project involved a survey of women who had recently 
given birth in which they were asked about their attitudes to and use of herbal medicines 
during pregnancy. During these interviews, it dawned on me how many pregnant women 
struggled with various pregnancy complaints and chronic illnesses that needed medical 
treatment, and how anxious these women were about using medicines during pregnancy. 
The result was that the conditions remained undertreated in many cases. At the same 
time, I also noted with great interest the more or less naïve attitude among many of the 
women towards herbal, ‘natural’ medicines. 
During my time working at a pharmacy after graduation, I further noticed that we 
received many enquiries from women suffering from nausea and vomiting during 
pregnancy (NVP). My impression from my encounters with these women was that, 
despite being ill, they were wary of using any medicines to relieve their symptoms. 
However, the majority tried both ginger and acupressure. Although my impression was 
that these treatments did not provide enough relief for many of the women, little more 
was done for them. They just ‘hung in there’. This aroused my curiosity as to what can 
be done for these women, and how should NVP be managed? What is safe to use for 
NVP? What do we know about the effectiveness and safety of ginger use during 
pregnancy? How are women with NVP treated in general? How are Norwegian women 
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Abstract 
Background: Nausea and vomiting during pregnancy (NVP) is one of the most 
commonly experienced pregnancy complaints and has been associated with decreased 
quality of life and occupational and daily life functioning, as well as negative 
socioeconomic consequences. Though several treatment guidelines exist for NVP, 
including recommendations for medicines that are safe to use during pregnancy, we 
know little about how this condition is managed, both internationally and nationally in 
Norway. We also know little about attitudes to treatment of this complaint. Ginger is 
included in most guidelines. However, only one study exists that was designed to 
investigate the safety of its use during pregnancy.  
Objectives: The main aim of this doctorial work was to explore various aspects of 
treatment of NVP. The specific objectives were: 1) to investigate whether exposure to 
ginger, a common NVP herbal drug, was associated with an increased risk of congenital 
malformations or other selected negative pregnancy outcomes; 2) to explore patterns of 
and factors related to NVP and its treatment across countries in Europe, North America, 
and Australia; 3) to explore thoughts and attitudes among Norwegian pregnant women 
and GPs about the treatment of NVP, and to identify potential barriers to optimal care for 
women with NVP; 4) to investigate the treatments used for NVP according to NVP 
severity among women in Norway, and to assess whether maternal characteristics and 
attitudes were related to the use of pharmacological treatment of NVP. 
Methods: In order to address the above objectives, several methods and data sources 
were used. 1) The large population-based Norwegian Mother and Child Cohort study, 
which provides information on the use of ginger and several potential confounders, was 
linked to the Medical Birth Registry of Norway from which information on pregnancy 
outcomes was retrieved (Paper I). 2) The Multinational Medication Use in Pregnancy 
Study, a web-based cross-sectional study carried out among women and new mothers in 
18 countries (Paper II). 3) Focus group discussions were used to explore thoughts about 
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and attitudes to the treatment of NVP among pregnant women and general practitioners 
(Paper III). 4) A web-based cross-sectional study was conducted among pregnant women 
and new mothers in Norway with NVP (Paper IV).  
Results: The study in Paper I showed that the use of ginger during pregnancy was neither 
associated with any increased risk of congenital malformations nor with any increased 
risk of stillbirth/perinatal death, preterm birth, low birth weight, or low Apgar score. 
In the study in Paper II, nausea during pregnancy was reported by 73.5% of women, 
17.9% of whom used conventional medicines and 8.3% herbal medicines. The 
prevalence of self-reported nausea and its treatment varied across countries. Education, 
working status and folic acid use were significantly associated with the use of 
conventional medicines against nausea. Respondents who suffered from nausea also had 
a high burden of comorbidity. 
In the focus group study in Paper III, the GPs thought it was important to normalise NVP 
symptoms. However, the women felt that their distress due to NVP was trivialised by the 
GPs. The women were sceptical about using medicines while pregnant, and avoidance 
was sought despite being ill. The GPs, who appeared to be uncertain and rather 
restrictive with respect to medical treatment of NVP, seemed to regard sick leave as an 
important part of the treatment regime. The women had good experience of graded sick 
leave. 
The Norwegian study described in Paper IV showed that, of the 712 women who were 
included in the study, 8.7%, 61.7% and 29.5% had mild, moderate and severe NVP, 
respectively. A total of 38.9% women had used one or more antiemetics, of which 
meclizine was the most commonly used, closely followed by metoclopramide. Different 
drug utilisation patterns were found between the groups of women with mild, moderate 
and severe NVP, and many women with moderate and severe NVP had not used 
medicines for NVP (70.2% and 32.9%, respectively). Sick leave was prescribed without 
initiating medical treatment in the case of 62.1% of the women who had been on sick 
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leave. The women’s beliefs about medicines had an important impact on their use of 
medicines for NVP. 
Conclusion and implications:  The findings of this doctorial work show that there are 
potential areas for improvement with respect to the management of NVP. The findings 
indicate 1) a need to increase awareness among healthcare personnel of the great distress 
women suffering from NVP may experience, and 2) that it is necessary to educate them 
about the recommendations in guidelines for the treatment of NVP. Due to the pregnant 
women’s fear of teratogenic effects of medicines, balanced evidence-based information 
about the maternal and foetal risks of medicines for NVP and tailored risk 
communication are necessary in order to reassure pregnant women in need of NVP 
medication.     
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In the following introduction, the background to studying NVP, methods and knowledge 
gaps will be presented. This forms the basis for the PhD thesis. 
 1.1 Why study treatment of nausea and vomiting during 
pregnancy (NVP)? 
The study of NVP is of interest due to the condition’s high prevalence in the pregnant 
population, its potentially major consequences for both mother and child and its potential 
for progression to very severe symptoms, leading to hospitalisation. Moreover, NVP has 
been subject to much debate in recent years, being one of the most frequently given 
reasons for sick leave during pregnancy (1-3).  However, little is known about how 
women with this condition are treated, also in Norway. 
As for the general pregnant population, more knowledge is needed about the safety of 
use of medicines and herbal remedies against NVP, and their patterns of use. It is 
necessary to know what is used and by whom.  The characterisation of women who use 
conventional and herbal medicines for NVP is necessary in order to gain a better 
understanding of the users and/or non-users. In order to improve pharmacotherapy for 
women with NVP, more knowledge is needed about the rationale for the decision to use 
conventional and/or herbal medicines or to abstain from use. Although some previous 
studies have described the treatment of NVP and/or attitudes to treatment, for many 
countries little research has been done to characterise treatments used for this illness. 
Furthermore, little is known about various aspects of the treatment of NVP in a 
Norwegian population. Several cultural and socioeconomic differences characterising 
women in Norway as compared to other western countries may have an impact on the 
use of conventional and herbal medicines. The Norwegian population has a high 
standard of living and is generally highly educated. The healthcare system is well-
functioning and provides free and frequent antenatal consultations. In addition, 
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Norwegian employees are entitled to sickness benefits equivalent to full wages if 
occupationally disabled due to own illness (4).The sick leave may be fulltime or graded 
(part-time) (4), e.g. working 50% and being paid sickness benefits equivalent to 50% 
wages. 
Preventing suboptimal and incorrect use of treatment against NVP may lead to 
substantial improvements in the care of pregnant women suffering from NVP.  
 1.2 Thalidomide – the tragedy that shaped our beliefs 
In the early 1960s, the thalidomide tragedy struck the world, resulting in more than 
10,000 children born with major malformations (5, 6). Thalidomide was marketed in 
1957 in Germany, and later in over 46 countries worldwide, as a sedative and hypnotic 
for treating insomnia and anxiety. It was also found to be effective against symptoms of 
morning sickness (5). In the early 1960s, however, an association between in utero 
exposure to thalidomide and severe congenital malformations was suspected and 
independently reported by doctors McBride and Lenz (7, 8). As a consequence, the drug 
was withdrawn from the market (5). The critical period for maternal intake of 
thalidomide resulting in malformations is found to be between 20 and 36 days post 
fertilisation, and the risk of congenital malformations after exposure within this period is 
estimated to be between 20% and 50% (5, 9). Thalidomide intake, as repeated use or 
even as one single dose, caused a wide range of anomalies, with the most frequently 
reported being those affecting the extremities, including phocomelia and amelia, and the 
ears (5, 10). The survival rate is estimated to be between 40% and 70% (5).  
The consequences of the above-mentioned tragedy were: 1) the concept of a placental 
barrier was discarded (9); 2) the promulgation of new drug regulations in the USA 
stating that the efficacy and safety of a drug must be investigated for the conditions of 
use prescribed in its labelling (9); 3) the initial exclusion of, and continuing caution 
about including, women in clinical trials (11). Today, it is clear that most drugs are able 
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to cross the placenta to some extent (9). Indeed, other drugs are found to be teratogenic, 
e.g. valproic acid, warfarin and isotretinoin (10). Other agents, such as Bendectin®, were 
falsely accused of having teratogenic potential, leading to market withdrawal despite the 
fact that a thorough review by the U.S. Food and Drug Administration (FDA) and 
regulatory agencies worldwide did not detect any association between the doxylamine-
pyridoxine combination and teratogenic effects (12, 13). 
A common belief developed as a result of the new awareness; women should preferably 
abstain from using medicines during pregnancy, especially during first trimester, a belief 
that is still widespread among the general public, but is also found among healthcare 
providers and in guidelines. Since the use of conventional medicines is feared during 
pregnancy, the use of complementary and alternative medicine is embraced by pregnant 
women due to the common belief that they are safe because of the substances’ natural 
origin (14). However, their efficacy and safety when used during pregnancy is poorly 
studied, and little is known about the potential for interaction with other supplements 
and/or conventional medicines. Nevertheless, studies from developed countries have 
reported that 27% to 93% of pregnant women use medicines, and approximately 40% 
use herbal medicines (15-18). 
Major congenital malformations occur in 1–3% of the general population at birth (10). 
Among these, it is worth noting that only 2–3% are thought to be related to drug 
exposure (10). Moreover, the prevalence of congenital malformations has not increased 
over the last half century despite the introduction of several new pharmaceutical agents 
on the market (19). Pregnant women get sick, and sick women get pregnant, which 
means that pharmaceutical treatment is essential for many pregnant women. Because 
some disease states, if untreated, pose a greater risk to the pregnancy than the treatment 
itself, e.g. epilepsy, depression and asthma, the avoidance of medical treatment can 
represent a direct danger to the women and their pregnancies (19). The costs, both 
psychosocial and financial, of teratogenic therapies are acknowledged. However, what 
about the costs of inadequately treated diseases of pregnancy – growth restriction, 
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pregnancy loss, preeclampsia/eclampsia (20), and also severe nausea and vomiting 
during pregnancy? The situation today is that most medications are marketed without an 
established safety profile for pregnant women, the result being extensive off-label use 
during pregnancy (11). Furthermore, there is a lack of development of drugs for use in 
obstetrics. Consequently, pregnant women are excluded from the therapeutic advances 
expected from modern drug research and development (11).  
 1.3 Historical perspectives on the treatment of NVP 
The first references to vomiting in early pregnancy date from as early as about 2000 B.C. 
in a papyrus that is part of the Petrie collection (21). It has since engaged numerous 
authors who have theorised on the subject. The aetiology has been attributed to various 
factors during history (21, 22). The first cases of excessive vomiting with fatal 
consequences reported in the medical literature date back to 1706 by Kerkring, and 1827 
by Dance (21, 22). In 1933, Kemp referred to NVP/hyperemesis gravidarum (HG) as a 
‘disease of theories’ (21, 23), a description that is still quite relevant. 
Historically, it has been held that vomiting of pregnancy is a psychosomatic illness (24). 
It has been alleged that women with severe nausea and vomiting transform psychological 
distress into physical symptoms (24). Several theories have been suggested. For instance, 
NVP has been described as a reflection of the mother’s resentment of the pregnancy, and 
vomiting as an attempt by the mother to expel the foetus orally (24, 25). Others have 
proposed that NVP is an unconscious mechanism resulting from a conflictual 
relationship with one’s own mother or husband (24, 25). 
Fairweather reviewed treatments against hyperemesis in 1968, restricting the survey to 
the years after 1938, and concluding that it was clear that no uniform strategy was 
applied (21). Though some of the treatments are recognised and still applied in today’s 
practice, such as antihistamines, vitamins and chlorpromazine, there are some that are 
quite obscure (see Figure 1): intramuscular injections of husband’s blood, intravenous 
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honey and inductive current (21). Other approaches cited in the literature include 
isolating the patient, denying her a vomit bowl and instructing her to vomit in the bed, 
and leaving it to herself to clean up after vomiting occurs (26). The wide range of types 
of treatments applied probably reflects the lack of a recognised aetiology.  
Note that Fairweather claimed as early as 1968 that ‘The value of drug therapy, if any, 
comes at the stage of morning sickness, when any of the present-day antiemetic group 
may be used to counter the feeling of nausea. If one can control symptoms at this stage, 
then it is likely that a large number of women can be prevented from developing 
excessive vomiting which if prolonged leads to metabolic disturbances’ (21). 
Figure 1. An illustration of the management of NVP, historically and today. Based on 
Fairweather and selected guidelines (21, 27-36). Abbreviations: NVP, Nausea and vomiting 
during pregnancy; ACTH, adrenocorticotropic hormone. 
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 1.4 Nausea and vomiting during pregnancy  
 1.4.1 Prevalence and definition 
NVP is one of the most commonly experienced pregnancy complaints, affecting 
approximately 70% of the pregnant population (37). The symptoms of NVP vary from 
mild nausea, gradually increasing in severity to frequent and persistent vomiting 
associated with severe morbidity, therapeutic abortion and even mortality if not treated 
properly (38-40). Hyperemesis gravidarum (HG) represents the most severe end of the 
NVP symptom spectrum, affecting approximately 1% of pregnant women (37). HG is 
considered to be a continuum of NVP following a gradual progression of severity of 
NVP symptoms (32, 41).  
NVP-related diagnoses are clinical diagnoses without uniform criteria (31). In 1968, 
Fairweather defined HG as vomiting occurring in pregnancy before the 20th week of 
gestation, and of such severity as to require hospital admission, without coincidental 
medical conditions (21). It was later revised by others to include persistent nausea and 
vomiting leading to dehydration, weight loss of more than 5% of maternal pre-pregnancy 
weight, ketonuria, and electrolyte imbalance (42). The International Statistical 
Classification of Diseases and Related Health Problems 10th Revision (ICD-10) uses the 
codes O21.0 and O21.1 for ‘Mild hyperemesis gravidarum’ and ‘Hyperemesis 
gravidarum with metabolic disturbance’, respectively (43). Mild HG is defined as ‘HG, 
mild or unspecified, starting before the end of the 22nd week of gestation’, whereas HG 
with metabolic disturbance is defined as ‘HG starting before the end of the 22nd week of 
gestation, with metabolic disturbance such as: carbohydrate depletion, dehydration 
and/or electrolyte imbalance’ (43). However, no universally accepted criteria distinguish 
between the mild and severe disease (31).  
The national guidelines issued by the Norwegian Society of Obstetrics and Gynecology 
(NGF) categorises NVP in three categories: mild, moderate and severe, according to the 
24-hour Pregnancy-Unique Quantification of Emesis (PUQE) scale (34, 44). The PUQE 
 22 
scale was developed by Motherisk, Toronto, Canada and assesses the severity of NVP 
(44).  
NVP is often referred to as a diagnosis of exclusion, and it is important to rule out other 
possible causes of the symptoms. It is worth noting that NVP that develops after 
pregnancy week 9-10 is rare, and the presence of fever, abdominal pain and tenderness, 
diarrhoea, constipation, headaches and palpable goitre is atypical in women with NVP, 
suggesting another cause than NVP (13, 32, 41, 45) (pregnancy week is in this thesis 
defined as: gestational week calculated from the last menstrual period before pregnancy). 
Differential diagnoses include for instance viral and bacterial infections, preeclampsia, 
food poisoning, gastrointestinal disorders (e.g. gastroenteritis, appendicitis, hepatitis, 
pancreatitis), pyelonephritis, kidney stones, metabolic disorders (e.g. hyperthyroidism, 
Addison’s disease, porphyria and diabetic ketoacidosis) and diseases of the central 
nervous system (e.g. migraine headaches and tumours) (13, 27, 32).  
 1.4.2  Physiology and description of the symptoms 
Nausea and vomiting have many causes, of which pregnancy is one (46, 47). The central 
neural regulation of vomiting is allocated to the vomiting centre and the chemoreceptor 
trigger zone (CTZ) in the area postrema located in the medulla (46, 47). The CTZ is not 
protected by the blood-brain barrier and is therefore sensitive to chemical stimuli, also 
by circulating toxins. CTZ is an important source of stimulation of the vomiting centre 
and the main site of action of many antiemetic drugs (46, 47). The CTZ has many 
dopamine D2 receptors and serotonin 5HT3 receptors, and the transmission from the 
vestibular apparatus to the vomiting centre involves cholinergic and histaminergic 
synapses (46, 47). The vomiting centre receives afferents from the limbic cortex, CTZ, 
nucleus solitarius, spinal cord and the vestibular system. Though not fully known, the 
neurotransmitters considered to be involved in the control of vomiting are acetylcholine, 
histamine, serotonin and dopamine.  
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Even though NVP is known colloquially as morning sickness, NVP symptoms occur 
after midday in the majority of the women with NVP (41). Typically, the symptoms 
initiate in the 6th gestational week, 90% experience the onset of NVP before the end of 
week 8, with a peak in intensity around weeks 8–13, before gradually declining during 
the second trimester (48-50). For most women, the symptoms resolve by the end of week 
16. However, 10% still experience symptoms after pregnancy week 20-22 (48, 49, 51). 
NVP typically follows an episodic pattern, in which 85% of the women with NVP 
experience at least two episodes with symptoms per day, the majority of which (70%) 
last 1–4 hours (41). Nausea is repeatedly described as the most distressing symptom (41, 
52-54). Vomiting occurs in approximately half of the pregnant population (48, 49, 51). 
Vellacott et al. reported daily vomiting in 28% of the women with NVP (50). One study 
revealed that the intensity of NVP at 11 weeks of gestation was comparable to the 
intensity of nausea symptoms experienced by patients with moderately emetogenic 
chemotherapy (49). Note that HG patients were excluded from this study. Although the 
prevalence of NVP gradually declines in the second trimester, for the women who 
continue to experience NVP, the intensity of symptoms tends to remain fairly stable 
(49).  
A variety of instruments have been utilised to measure the severity of NVP symptoms, 
including the Rhodes Index, the Nausea and vomiting in pregnancy instrument, the 
McGill Nausea Questionnaire, the Hyperemesis Impact of Symptoms Questionnaire, and 
PUQE (44, 49, 55-58). The severity of symptoms has also been determined based on the 
presence of nausea with/without vomiting, the numbers of hours of nausea, the number 
of vomiting episodes, diagnosis of HG, presence of HG defined as admission to hospital 
with/without dehydration, electrolyte disturbances, 5% pre-pregnancy weight loss, 
ketonuria or single/multiple admissions (41, 48, 59-62). This heterogeneity makes 
comparison of symptom severity between different studies challenging. 
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 1.5 Aetiology 
Comprehending the full aetiology of an illness may lead to the identification of effective 
treatments. Several mechanisms have been proposed in an attempt to explain the 
aetiology of NVP, but no firm conclusions can be drawn, due to the varying definitions 
of HG and/or NVP, small studies and differing assay methodology applied in the 
hormone measurement studies (63). It is possible that HG is caused by a yet unidentified 
factor, or that HG is the end result of various conditions. However, NVP/HG is 
frequently assumed to have a multifactorial cause (40). While NVP affects the large 
majority of pregnant women to some extent, only a minority develop severe NVP/HG. In 
order to explain why some women develop more severe symptoms, Bogen and Goodwin 
both introduce the concept of differences in the individual’s response to the causative 
agent, depending on her susceptibility mediated by vestibular, gastrointestinal, olfactory 
and behavioural pathways (64, 65). The fact that no single theory has been identified 
certainly complicates the management of this condition (63). 
Several factors have been associated with NVP in the literature (41). The results from 
many of the studies are conflicting, however, probably due to differences in 
methodologies and definitions of NVP and HG. Again it is difficult to distinguish 
between risk factors for NVP and HG, as the definitions for the two conditions vary in 
the literature. However, in an extensive review by Gadsby and Barnie-Adshead, the 
following factors were identified as being associated with an increased likelihood of 
NVP or HG: NVP in previous pregnancies, non-smoking, nausea when previously taking 
an oral contraceptive, hydatidiform mole, twin pregnancy, increase in food cravings and 
aversion, and excessive caffeine-intake (41). HG alone was associated with having a 
mother who had suffered from HG, younger age (<26 years of age), nulliparity, a 
previous unsuccessful pregnancy, reduced maternal weight gain in current pregnancy 
and female offspring (41).  
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Various theories have been proposed for the aetiology of NVP, but a combination of 
several factors is probably involved (66):  
 Evolutionary perspective: One theory is that normal levels of NVP protect pregnant 
women and their foetuses against harmful substances in food (67). 
 Genetic: NVP and HG show patterns of familial aggregation. A higher risk of severe 
NVP/HG is found among women with mothers and/or sisters who have experienced 
severe NVP/HG (50, 68, 69). Monozygotic female twin pairs are found to be more 
concordant than dizygotic female twin pairs in relation to experiencing NVP (70).  
 Endocrine: Hormonal changes occurring in pregnancy are thought to be part of the 
aetiology of NVP and HG, and the most commonly proposed hormones involved 
include the human Chorionic Gonadotropin (hCG), oestrogen, progesterone and 
thyroid hormones (71). Eleven of 15 studies published since 1990 showed a 
significantly higher level of serum hCG among women with HG compared to 
controls, but its role in the pathogenesis remains elusive (63). Furthermore, the 
current literature does not suggest that the aetiology of HG can be explained by the 
role of progesterone or oestrogen alone, and their relationships with NVP have been 
inconsistent between studies (63, 72). Since hCG and thyroid stimulating hormones 
are structurally related, the observed association with hyperthyroidism may be 
explained by characteristics facilitating highly stimulating properties of the thyroid 
gland among women with HG (63, 65, 73). However, since hyperthyroidism itself is 
seldom a cause of nausea and vomiting, the focus is switched back to hCG (65).  
 Gastric dysrhythmias: Changes in gastric rhythmic activity may contribute to NVP 
(74). The intensity of nausea is significantly greater in pregnant women with gastric 
dysrhythmias than in those with normal electrogastrographic patterns (74). 
 Helicobacter pylori (H. Pylori): There is evidence suggesting an association between 
H. pylori infection and hyperemesis gravidarum (75, 76). Whether treatment for H. 
pylori in H. pylori-positive HG women is a useful strategy for shortening symptoms 
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of HG has not been thoroughly studied, but this may represent a new therapeutic 
option (76).  
 Psychological factors: As already described in section 1.3, NVP has been believed 
to have a psychosomatic explanation. However, both Buckwalter and Munch 
question the validity of these beliefs due to the lack of methodologically sound 
studies (24, 77). Both authors draw attention to the problem of gender bias to explain 
the pervasiveness of the assumption that HG is of psychosomatic origin. It is 
suggested that there is a psychological component to more severe NVP and HG that 
can be explained by the severe, continuing and incapacitating physical symptoms that 
result in psychological stress and trauma (78). Indeed, symptoms of depression and 
anxiety have been associated with NVP and HG, as well as posttraumatic stress 
syndrome (79-82).    
In conclusion, the inconclusive evidence means that a single cause cannot be determined 
(63). Though some of the proposed mechanisms provide reasonable explanations, there 
is still a need for more knowledge and understanding of the causes and their possible 
interconnection (63, 65). Moreover, studies on NVP should include information about 
these factors if possible, as they may be important to our understanding of this illness. 
As long as NVP’s exact aetiology is unknown, treatment is problematic since the optimal 
targets are unidentified. 
 1.6 Impact of NVP 
The importance of studying NVP becomes apparent in light of current knowledge of the 
possible impact of NVP on women, their families and on society. 
 1.6.1 Pregnancy outcomes and foetal complications 
NVP symptoms in general have been associated with decreased risk for miscarriage and 
early delivery (41, 72, 83). However, there is evidence that severe HG is associated with 
a higher incidence of children with low birth weight (LBW), small for gestational age 
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(SGA) children and preterm delivery (84). However two large registry-based studies, 
recently conducted in Norway, detected no clinically significant impact on HG on 
pregnancy outcomes (85, 86). Some authors argue that HG itself is not thought to be a 
risk factor for the negative pregnancy outcomes, which are instead thought to be 
mediated through low weight gain during pregnancy (<7 kg) as a consequence of severe 
NVP/HG (87, 88). Women with weight gain of <7 kg has been found to have an 
increased risk of having SGA-children and preterm delivery (87, 88). Little is known 
about the long-term health effects on infants born to mothers whose pregnancies were 
complicated by HG. Of potential relevance to HG is the findings by Roseboom et al., 
who found that poor maternal nutrition during pregnancy, especially in early gestation, 
during the Dutch famine, was shown to imply lasting negative consequences for the 
child’s health, independently of the child’s size at birth (89). Indeed, two studies found, 
firstly, that children aged 8 to 9 years had a higher risk of neurodevelopmental diagnosis, 
and, secondly, that adults exposed to HG in utero had a higher risk of behavioural or 
emotional disorders (90, 91). A third study reported lower insulin sensitivity among 
children aged 4 to 11 years born to mothers who had experienced HG, compared to 
controls (92). It has also been speculated whether HG offspring have an increased risk of 
cancer, but no firm evidence yet exists (93).  
 1.6.2 Maternal complications 
Psychosocial morbidity in pregnant women with NVP is substantial, and in many cases, 
underemphasised (72). Awareness of the high burden that NVP represents for the 
women highlights the need to take this condition seriously. 
NVP has been shown to have a profound impact on a woman’s life, negatively affecting 
quality of life, daily activities, her relationship with her partner, parenting, social 
functioning and occupation (52, 53, 57, 94, 95). Women with moderate to severe NVP 
have been found to have a quality of life comparable to women with recent breast 
cancer, myocardial infarction or postpartum depression (94). Moreover, women with 
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NVP had lower Short Form-36 domain scores in physical functioning, physical role, 
bodily pain, vitality, social functioning and emotional role compared to healthy pregnant 
women and women with clinical depression (57). Though the effects are magnified when 
symptoms are moderate or severe, even mild NVP can have significant adverse effects 
on a woman’s life (53, 95). 
Women describe feelings of isolation, fatigue, depression and helplessness due to nausea 
(53, 82, 96). Family planning is affected in women with severe symptoms; up to 15% of 
those with severe symptoms have been reported to terminate an otherwise welcome 
pregnancy, and almost 40% are reported to being considering or planning to avoid 
further pregnancies, illustrating how debilitating severe NVP can be (38, 39, 96, 97). 
Importantly, the women who performed elective termination of pregnancy were more 
than three times more likely to report a negative attitude from their caregiver than 
women who did not terminate their pregnancy (38).  
Although Lacasse et al. found an inverse association between increased severity of NVP 
and decreased quality of life (94), work by Munch et al. suggests that perceived physical 
symptom severity and multiple psychosocial factors are equally or more important 
contributors to low quality of life than having an HG diagnosis (98). Women with NVP 
may experience an equally significant negative impact on quality of life as HG patients if 
they perceive their physical symptoms to be severe (98). This is in line with Mazzotta et 
al., who concluded that psychosocial morbidity is evident across the different degrees of 
NVP, even among women with mild NVP symptoms (53). Note that among women with 
mild symptoms, 21%, 36% and 43% reported feeling depressed due to NVP always or 
most of the time, an adverse effect on their relationship with a partner and an adverse 
effect on the partner’s daily life, respectively (53). Furthermore, compared to vomiting, 
nausea alone is reported three times more frequently to be the most troublesome 
symptom (53). 
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If inadequately managed, HG can cause significant maternal complications as a result of 
vitamin deficiency, electrolyte abnormalities, dehydration, protein and energy 
malnutrition, as well as psychological morbidity (40, 99). Vitamin B1 (thiamine) 
deficiency can cause Wernicke’s encephalopathy (40, 100, 101). Acute encephalopathy 
is triggered by the ingestion of carbohydrate-rich food and intravenous administration of 
dextrose or glucose, since the metabolism of the carbohydrates consumes the available 
thiamine (40, 100). Vitamin B6 (pyridoxine) and vitamin B12 (cobalamin) deficiencies 
can result in anaemia and peripheral neuropathies (40, 102). An abnormal coagulation 
profile and bleeding have also been described as a result of Vitamin K deficiency (103), 
while hypokalaemia and hyponatraemia can cause central pontine myelinosis (101). 
Increased risk of thrombosis is due to dehydration and immobility (40). In addition, 
Mallory Weiss tears (oesophageal rupture) have been described as a consequence of 
mechanical forces (40, 63).  
Fatal outcomes due to HG are rare nowadays, which can be attributed to better treatment 
with restoration of fluid and electrolyte balance, which was more thoroughly understood 
in the early 1940s (21, 99, 104). A dramatic decrease in the maternal mortality rate was 
observed in the UK as a result, dropping from 159 per million in the period 1931to1940, 
to 3 per million observed in the period from 1951 to 1960 (104). However, the latest 
death in Norway as a consequence of HG was in 2004, as a result of malnutrition (105, 
106).  
 1.6.3 Socioeconomic consequences 
NVP is one of the most common reasons for sick leave during pregnancy (3), and it 
represents a significant socioeconomic burden for women and for society (107, 108). HG 
is also responsible for large expenditures, being the most common reason for 
hospitalisation in the first half of pregnancy and the second most common reason for 
hospitalisation during pregnancy overall (109, 110). Moreover, about 25% of women 
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with HG require multiple admissions (41). SGA and LBW-children are also at risk of 
needing costly neonatal and paediatric treatment. 
 1.7 Management of NVP  
Due to the multi-faceted aetiology of NVP so far described, it is not surprising that 
treatment has been attempted by countless methods and drugs throughout history (21) 
(see also Figure 1). However, as no exact aetiology has been determined, today’s 
treatments aim to treat the symptoms, not the illness. The goal of treatment should be to 
improve the symptoms while at the same time minimising maternal and foetal 
complications and risks (31). As elaborated above, severe NVP symptoms have been 
associated with severe morbidity and shown to have major impact on the women’s lives 
(72), implying that preventing, or reducing the intensity of severe symptoms should be 
of high priority.  
A multimodal, individually tailored approach is usually needed to achieve this goal. The 
choice of treatment should be based on the severity of symptoms and their impact on the 
woman. Treatment ranges from dietary modifications, pharmacological treatment to total 
parenteral nutrition (72). 
Treatment of early symptoms may prevent progression to HG and more serious 
complications and hospitalisation (32). The benefit of early treatment was discussed 
already in 1968 by Fairweather, who argued that, if the symptoms can be controlled at 
‘the stage of morning sickness’ it is likely that the development of excessive vomiting 
will be prevented in many cases (21), which is a viewpoint consistently held in North 
American guidelines (30, 32). The findings of Neutel and Johansen support this (12, 
111). Bendectin®, a combination of doxylamine succinate and vitamin B6/pyridoxine 
(also including dicyclomine before 1976), was the drug of choice for NVP in the USA 
and several other countries under other trade names from 1956 to 1983 (112). After the 
withdrawal of the antiemetic Bendectin® from the market in 1983, there was a marked 
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increase in the hospitalisation rates due to severe NVP/HG between 1983 and 1989 
following reduced sales of Bendectin® (see Figure 2) (12, 111). The Canadian generic 
product Diclectin®, a combination of doxylamine and vitamin B6, remained on the 
Canadian market, and in 1990, its use started to increase. In the period 1992–1995 a 
reduction in the number of hospitalisations due to severe NVP/HG was observed (111). 
 
Though no rigorous studies are available to verify this, pre-emptive treatment of NVP 
among women with a history of severe NVP or HG was found to reduce the risk of 
moderate and severe NVP symptoms (113, 114). Furthermore, prophylactic treatment of 
nausea and vomiting is a common strategy applied to prevent nausea and vomiting 
related to other conditions, such as chemotherapy and motion sickness (115, 116). 
Together, these strategies indicate that it is advantageous to start treatment before 
symptoms have become more severe.  
According to a Canadian study, only half of the women with NVP had been asked about 
the severity and intensity of their symptoms, and even fewer (22%) were asked about 
their symptoms’ impact on daily tasks (117), illustrating that there is a need for 
improvements in pregnancy care for women with NVP.   
Figure 2. From: Neutel CI: 
Variation in rates of 
hospitalisation for 
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Various guidelines addressing the treatment of NVP/HG exist in Norway and 
internationally (27-36). For the purpose of this thesis, the following guidelines have been 
reviewed, with specific focus on the drugs available in Norway and/or recommended in 
Norwegian guidelines: Norwegian guidelines, such as the National clinical guideline for 
antenatal care, Norwegian Medicines Handbook, Norwegian Electronic Medical 
Handbook (NEL), and the Obstetric Guidelines issued by the Norwegian Society of 
Obstetrics and Gynecology (NGF) (33-36); and other major guidelines considered 
relevant, such as UpToDate, National Institute for Health and Care Excellence (NICE) 
guidelines, BMJ Best Practice, and the North American guidelines issued by the 
American College of Obstetricians and Gynecologists, the Society of Obstetricians and 
Gynaecologists of Canada and the Motherisk (27-33). The Norwegian guidelines, 
together with NICE guidelines, are generally more restrictive than the other international 
guidelines in that they specifically state that NVP is considered a normal part of being 
pregnant, that pharmacologial treatment is rarely necessary and that one should be 
generally restrictive as regards the use of antiemetics (28, 34-36).  
 1.7.1 Dietary and lifestyle changes 
The guidelines typically include recommendations to start with advice about food and 
dietary changes, avoidance of triggers and treatment with alternative approaches such as 
acupressure and ginger (27-36). Dietary and lifestyle changes usually include advice 
about eating small and frequent meals, avoiding spicy or fatty foods, and eating bland or 
dry foods and foods that are higher in protein. There is little scientific evidence of the 
effect of dietary changes on nausea, although some evidence supports the view that 
protein-predominant meals reduce nausea (118). In addition, a Norwegian study found 
that women adhering to a diet characterised by fish, vegetables and whole grain prior to 
pregnancy were less susceptible to developing HG (119). Adequate intake of liquid is 
important to avoid dehydration, and cold beverages, carbonated or sour, in small 
amounts between meals are thought to be better tolerated by women (45). Several 
guidelines refer to the work by Bischoff that describes dietetic strategies of relevance to 
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the management of nausea (120). In addition, avoidance of triggers such as odours, heat, 
humidity, noise, and visual and physical motion is recommended. Other 
recommendations include having a snack in bed before getting up in the morning, and 
getting enough rest. Motherisk in Toronto, Canada has extensive clinical experience and 
has issued detailed dietary and lifestyle advice, see Box 1.  
Box 1. Dietary and life style advice adapted from Maltepe and Motherisk (45, 121). 
 
Dietary strategies 
 Eat small amounts of food every 1 to 2 hours. Avoid feeling too hungry or thirsty. 
 High-carbohydrate, low-fat foods are easier to digest. 
 Eat bland, dry or salty foods. Avoid spicy, fried and/or high fat foods. 
 Add any source of protein to each meal and snack (such as nuts, seed, dairy etc.). 
 Do not eat and drink at the same time, try to drink 20 to 30 minutes before or after 
meals and snacks 
 Aim at 8 cups of daily fluid intake. Drink colder fluids, such as ice chips, slushies, 
popsickles or smoothies to increase tolerability. 
 Consider adding oral rehydration products such as coconut water, sport drinks or 
jello made with unflavoured electrolyte solution. 
 Consider adding liquid supplements, bars or puddings if unable to keep food down. 
 For constipation, try to increase dietary fibre intake along with fluid. 
Life style strategies 
 Get plenty of sleep and rest. 
 To minimize food and odour aversions, ventilate, get fresh air, consume meals 
lukewarm/cold. 
 To reduce metallic, bitter, sour or odd taste in mouth, try candies or gums, and drink 
ice-cold fluids 
 Have a snack before getting up in the morning. 
 Spit out excess saliva, and do frequent mouthwash. 
 Iron in the prenatal multivitamin may case additional NVP and/or constipation. If 
normal iron level, try to switch to a multivitamin with lower iron and add folic acid. If 
low iron levels, split prenatal vitamin taking one half in the morning and one half in 
the evening. 
 Treat symptoms of heartburn and reflux which may aggravate NVP symptoms. 
Bottom line 
 Eat anything that agrees with you and stays down. 
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 1.7.2 Complementary and alternative medicine (CAM) 
Ginger 
Ginger is included in all the reviewed guidelines. Ginger rhizome (Zingiber officinale 
Roscoe) has a long tradition for use against nausea (122), and is one of the most 
commonly used herbs during pregnancy (14). Several of the studies published in the last 
decade report prevalence rates of over 10% (17, 123-125). The mechanism of action 
remains uncertain, although it is proposed that it is attributable to the ability of the 
components of ginger to affect serotonin and muscarinic receptors in the gastrointestinal 
tract (126). A possible antiemetic effect via the central nervous system has also been 
proposed (127).  
The effectiveness of ginger against NVP has been investigated in several studies (Table 
1), and it has been found to be more effective than placebo, equally or more effective 
than vitamin B6, and as effective as acupressure, pyridoxine-doxylamine and 
dimenhydrinate (128-140). Moreover, when compared to metoclopramide, there were no 
statistically significant differences in the observed trend of nausea or vomiting severity 
(141). However, the authors conclude that metoclopramide is more effective than ginger, 
but this is difficult to read from the published results (141). The most commonly used 
doses were between 1 g and 1.5 g per day of dried ginger root powder equivalent. One 
review investigating the effect of ginger on relieving NVP reports that ginger is superior 
to placebo (142). This is supported by a second review concluding that ginger relieved 
nausea symptoms, but did not significantly affect the number of vomiting episodes 
(143). The latest Cochrane review of treatments of NVP concludes that ginger may be 
helpful to women, but that there is limited and inconsistent evidence of its effectiveness 
(144). The conflicting conclusion is probably due to the stricter study inclusion criteria 
applied by the authors of the Cochrane review.    
Information about the safety of ginger use during pregnancy is mainly derived from the 
clinical trials, which were generally underpowered to detect any differences between the 
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groups (144). Nevertheless, no increased risk of negative pregnancy outcomes is 
reported (143). Most textbooks therefore classify ginger as safe during pregnancy, which 
is mainly based on a lack of case reports of negative outcomes (9, 145, 146). Caution is 
therefore recommended (9, 145, 146). Some specific concerns are also raised by certain 
authors. Women with a history of miscarriage, vaginal bleeding, or clotting disorder are 
advised to avoid ginger during pregnancy (147), and it is deemed to be contraindicated 
close to labour due to a feared increased risk of post-partum haemorrhage (148). These 
concerns probably stem from ginger’s ability to inhibit thromboxane synthetase and 
thereby platelet aggregation in vitro (149). However, the consequence of this property in 
vivo is controversial (150-152). Backon has also raised a theoretical concern about 
ginger’s ability to affect testosterone receptor binding which may have implications for 
the sex differentiation of the foetal brain (153), but this has not been confirmed by other 
studies. One study has been conducted to specifically investigate the safety of use of 
ginger during pregnancy (154). The study, which included 187 women, did not detect 
any statistically significant differences between the ginger group and the control group 
with respect to malformations, live births, spontaneous or therapeutic abortions, still 
birth, birth weight or gestational age after ginger use during pregnancy (154).  
Commonly reported side effects include heartburn and belching, and higher doses of 
ginger seem to correlate with more heartburn (132, 143). Many women suffering from 
NVP also struggle with heartburn and reflux problems (155) that, consequently, may be 
exacerbated by ginger intake. Though ginger has proven effective against NVP in many 
studies, a recent survey among women with HG in the UK reported unpleasant side 
effects such as pain and/or burning during vomiting and acid reflux or heartburn, as well 
as lack of effectiveness, thereby implying that ginger should not be recommended to the 
HG patient group (156).  
 
In line with several of the guidelines, the Norwegian guidelines from NGF recommend a 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Acupuncture and acupressure 
Acupressure and/or acupuncture of the P6 (Neiguan point) are mentioned in several of 
the guidelines (27-36). Though the therapies appear to be safe to use during pregnancy 
(30, 31), it is pointed out that the evidence supporting their use is scarce, with conflicting 
results and the existence of significant methodological flaws (32, 144, 158). The 
Cochrane review from 2014 concludes that there is some evidence of the effectiveness of 
P6 (Neiguan) and auricular acupressure in use against NVP (144), which is in line with 
another review (158). However, the authors found no significant benefit of acupuncture 
(P6 or traditional) for NVP (144). 
Vitamin B6 
Vitamin B6, pyridoxine, is recommended either as a single agent or in combination with 
doxylamine or another antihistamine (27, 29-34). Vitamin B6 is found to be beneficial 
for use against NVP (159, 160). According to Matthews et al., who were behind the 
Cochrane review, vitamin B6 is found to be effective in reducing nausea, but to have no 
effect on vomiting (144), and a daily dose of 10 mg was favoured over a lower dose of 
1.28 mg (161). The Norwegian guidelines from NGF recommend a treatment regime of 
either 25 mg 4 times daily or 40 mg 2 times daily, not exceeding 200 mg daily (34). 
Tablets containing 40 mg are available in Norway. 
It is worth noting that the Norwegian Medicines Handbook states that vitamin B6 has no 
more effect than placebo on NVP (35). Moreover, NICE does not currently recommend 
pyridoxine due to concerns about toxicity at high doses (28). Cases of neuropathy have 
been described after high doses of pyridoxine intake, substantially exceeding the doses 
recommended for NVP (102). In most cases the intake was higher than 2 g, although an 
intake of 200 mg over a long period of time (>3 years) was also reported (102). 
However, as one of the constituents of Diclegis®/Diclectin®, and formerly Bendectin®, 
pyridoxine’s safety has been widely studied, and no increased risk of birth defects has 
been detected (162). 
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 1.7.3 Pharmacological treatment 
There are several antiemetics available to help alleviate NVP symptoms. The medicines 
described in the Norwegian guidelines and/or available on the Norwegian market are 
listed in Table 2.  
Table 2. An overview of medicines for the treatment of NVP available on the Norwegian market 
or described in the Norwegian guidelines. 





Metoclopramide Afipran ® 
Prochlorperazine  Stemetil ® 
Chlorpromazine Largactil® (currently not 
marketed) 
Ondansetron Zofran ® 
 
The best course of treatment on the basis of evidence-based individual evaluations of 
effect and safety should be sought. UpToDate recommend that patients are continued on 
a particular medicine for several days to determine whether the symptoms are improving 
(31). While Canadian guidelines and UpToDate advise adding new medicines in their 
algorithm (29-31), the Norwegian guidelines from the NGF state that a medicine is 
traditionally discontinued before starting up a new one, adding that, in theory, a 
combination of medicines acting through different mechanisms of action may be 
beneficial, but that the evidence of a potential benefit is scarce (34). However, 
combination therapy is a commonly applied strategy in the treatment of chemotherapy-
induced nausea and vomiting (115). According to the Motherisk NVP protocol, women 
should be advised to take their medicines daily and consistently to control the symptoms, 
and gradually taper off the medicines upon improvement (45). UpToDate recommends 
continuing the drug regimen that is effective until the patient has been asymptomatic for 




Antihistamines are regarded as first line treatment when dietary and lifestyle changes 
and/or complementary therapies fail to relieve the symptoms (28, 30-36). Antihistamines 
act directly on the vomiting centre and also on the vestibular system (47). Cholinergic 
and histaminergic synapses are involved in the transmission from the vestibular system 
to the vomiting centre (47). The antihistamines recommended in the Norwegian 
guidelines are meclizine and promethazine (33-35), while cyclizine is included in the 
Danish guidelines and UpToDate (31, 163).  
Antihistamines are reputed to be safe to use during pregnancy. A meta-analysis of 24 
trials involving more than 200,000 women found no increased risk of teratogenic effects 
after use of antihistamines during the first trimester (164). A re-analysis of the data 
included in the study by Seto et al. identified a total study population of 139,414 women 
of whom 23,485 had exposure to antihistamines, and no increased risk of malformations 
was detected (165). Together with a meta-analysis by Mazzotta and Magee, a Swedish 
study based on the Medical Birth Registry reinforced the perceived safety of 
antihistamines (166, 167). The Swedish study, which includes data on meclizine, 
cyclizine and promethazine, actually found a lower risk of low birth weight, prematurity, 
being small for gestational age and malformations associated with use of antihistamines 
(166). This is supported by data from the meta-analysis, which detected no increased risk 
of congenital malformations (166, 167). While meclizine was associated with increased 
risk of cleft palate in one study, this finding was only based on five exposed cases (168), 
and several other studies have not replicated this finding (169). A Swedish study 
including >16,000 exposed cases detected no increased risk of malformations, preterm 
birth, low birth weight, short body length and small head circumference after use of 
meclizine during pregnancy (170). Hence, a recent review focusing on antihistamines 
and birth defects concluded that the literature on safety of antihistamine use during 
pregnancy is generally reassuring, particularly for the first-generation H1-receptor 
antagonists (169). 
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While the latest Cochrane review concluded that there was limited evidence to support 
the use of pharmacological agents to relieve mild to moderate nausea, the meta-analysis 
by Mazzotta and Magee indicates that antihistamines are effective against NVP (144, 
167).  
The delayed release product containing doxylamine, 10 mg, in combination with 
pyridoxine, 10 mg, is probably the most extensively studied agent among the 
antihistamines (112). It has been studied for both effectiveness and safety (112). This 
combination in a delayed release formulation has been available since 1979 in Canada, 
and it was recently also approved by the FDA (112). According to current evidence, this 
combination is safe for mother and foetus, and superior to placebo for relieving NVP 
symptoms (162, 171, 172). The standard dosage regimen of the doxylamine-pyridoxine 
combination is up to four tablets per day (one in the morning, one in the afternoon and 
two at bedtime) (45).  
Promethazine is primarily an H1-receptor antagonist classified under antihistamines 
according to the Anatomical Therapeutic Chemical (ATC) classification system (173), 
although it is also a weak dopamine antagonist (31). Promethazine was found to have 
similar therapeutic effects to metoclopramide in patients hospitalised for HG (174), but 
the latter had a better side effects profile.  
The Norwegian guidelines recommend meclizine 25 mg 1-2 times daily or promethazine 
25 mg 2-3 times daily (33, 34). Cyclizine is also available on the Norwegian market, but 
is not included in the Norwegian guidelines. Danish guidelines recommend cyclizine 50 
mg three times daily (163). 





If antihistamines do not provide sufficient relief, a dopamine antagonist is usually the 
next step (27, 29, 31, 33-35). The dopamine antagonists mentioned in the Norwegian 
guidelines are metoclopramide, prochlorperazine and chlorpromazine (33-35).  
Metoclopramide is a D2 receptor antagonist that exerts its action in the chemoreceptor 
trigger zone and through a peripheral prokinetic action that increases the motility of the 
oesophagus, stomach and intestine (46). Metoclopramide may therefore be helpful for 
women with indigestion, or who vomit indigested food eaten many hours earlier (45). 
Large cohort studies have failed to demonstrate an increased risk of major 
malformations, low birth weight, preterm delivery, perinatal death, spontaneous abortion 
or stillbirth after exposure to metoclopramide during pregnancy (175, 176).  
Two randomised controlled trials (RCTs) found metoclopramide to be as effective as 
promethazine and ondansetron (174, 177), while another RCT found ondansetron to be 
superior to metoclopramide in controlling severe vomiting (178). A study that evaluated 
the effectiveness of three pharmaceutical regimens found that the regimen combining 
pyridoxine and metoclopramide was superior to either monotherapy of prochlorperazine 
or promethazine in the management of NVP (179). A retrospective database analysis, 
which compared outpatient regimes of subcutaneous infusion of ondansetron or 
metoclopramide for HG, found that more patients altered their treatment regime from 
metoclopramide to ondansetron than vice versa, with the most common indications being 
persistent severe symptoms or side effects (unspecified) (180). Lombardi et al. found 
that subcutaneous metoclopramide improved symptoms of NVP in 89% of the women, 
and alteration of therapy to subcutaneous ondansetron was required by 10.7% of the 
women, who were more likely to have a PUQE score ≥13 (181). As argued by Klauser et 
al., although each patient may respond differently to treatment due to the unique 
character of NVP, these results may indicate that ondansetron is superior to 
metoclopramide in managing severe NVP symptoms (180).   
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The Norwegian guidelines recommend 10–20 mg of metoclopramide three times daily as 
a tablet or a suppository (34). However, the suppositories were recently withdrawn from 
the Norwegian market.  
The phenothiazines prochlorperazine and chlorpromazine are antipsychotics that are also 
used as antiemetics during pregnancy (46). They are primarily D2 antagonists, but they 
also have some blocking effects on histamine and muscarinic receptors (46). Though 
there are isolated case reports of children born with malformations after exposure to 
prochlorperazine during pregnancy, Briggs et al. conclude that most evidence generally 
points to prochlorperazine being safe during pregnancy when used occasionally and in 
low doses (182-185).  These findings were supported by two other studies that failed to 
detect increased risk above baseline risk for birth defects among 704 and 224 infants, 
respectively, who were exposed to prochlorperazine during the first trimester (185, 186). 
Little evidence of effectiveness exists, although prochlorperazine seems to be effective 
for some patients (179). Norwegian guidelines recommend 5-10 mg tablets of 
prochlorperazine two to three times daily, or 25 mg in one daily administration as a 
suppository (33, 34). 
UpToDate specifically states that chlorpromazine is reserved for refractory cases (31). 
Some concerns have been raised about the high doses used in the treatment of 
psychiatric illnesses, although the doses used in the treatment of NVP are much lower 
(184). Consequently, though literature documenting the safety and effectiveness of 
chlorpromazine is scarce, the existing information is generally reassuring and the use of 
chlorpromazine for NVP is considered safe if used occasionally and in low doses (184, 
185, 187). Chlorpromazine is included in the Norwegian guidelines from NGF (34), 
despite not being currently marketed in Norway. Hence, in practice it is mostly used in 
hospitals through application. The recommended dosage of chlorpromazine according to 
Norwegian guidelines is 10 mg two to three times daily administered as tablets or as 25 
mg in a 1000 ml 5% glucose intravenous infusion administered over 24 hours (34). 
 45 
Common side effects of the dopamine antagonists in the phenothiazine group and 
metoclopramide are sedation and extrapyramidal symptoms, including dystonias and a 
risk of tardive dyskinesia (46, 188). In June 2013, the European Medicines Agency 
(EMA) issued a recommendation to change the use of metoclopramide due to a risk of 
serious neurological adverse events, such as extrapyramidal symptoms, including 
irreversible tardive dyskinesia (189). As a consequence, it was recommended to restrict 
the use of metoclopramide to maximum five days duration, with a maximum daily dose 
of three administrations of 10 mg (189). As five days’ treatment is seldom long enough 
to treat NVP, this change will probably limit metoclopramide’s role in the treatment of 
this pregnancy complaint. The consequence is that pregnant women are deprived of a 
commonly used agent that is currently known to be safe for the foetus when used during 
pregnancy, and women are left with fewer agents available for treatment of NVP. The 
FDA recommends a maximum duration of three months (190). Tardive dyskinesia, 
which is the most feared adverse effect,  is an extrapyramidal disorder characterised by 
potentially disfiguring and irreversible involuntary movements (191). According to a 
review from 2010, the risk of tardive dyskinesia is likely to be less than 1% (191). 
Although female gender has been associated with an increased risk of developing tardive 
dyskinesia, tardive dyskinesia is generally associated with advanced age (above 60 to 70 
years of age). However, young adults, especially girls aged 12 to 19 years, were also 
identified as having a higher risk of tardive dyskinesia (191), although the absolute risk 
of developing neurologic side effects of metoclopramide when used during pregnancy 
for NVP is not known.  
5-HT3-antagonists 
Ondansetron is a selective serotonin 5HT3 receptor antagonist. 5HT3 receptors occur in 
the peripheral nervous system, and in the brain in the CTZ (46, 47). Ondansetron has 
become a commonly used agent against NVP. A large US study of medication use 
during pregnancy reported that ondansetron was used by nearly 3% of the women 
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reported from the centres in Boston and Philadelphia during the period 2003 to 2008 
(192).  
Questions have recently been raised about the safety of ondansetron (193). Two Danish 
studies based on the Danish prescription register showed conflicting results with respect 
to the risk of malformations of the heart (194, 195). One of the studies detected an 
increased risk of heart defects in offspring (OR 2.0, 95% CI 1.3–3.1) (194). However, 
this result is derived from an abstract, as no full article has been published yet. The other 
study, published in the New England Journal of Medicine, did not detect any increased 
risk of congenital malformations, miscarriage, low birth weight or being small-for-
gestational-age (195). A Swedish study, which included 1349 infants exposed to 
ondansetron during early pregnancy, detected a modestly increased risk of 
cardiovascular defects (OR1.62, 95% CI 1.04–2.14) and cardiac septum defects (RR 
2.05, 95% CI 1.19–3.28) (196). An increased risk of isolated cleft palate (OR 2.37, 95% 
CI 1.18–4.76) was found in a smaller study that included 55 first trimester exposures 
(197). Hence, it is recommended to avoid use before pregnancy week 10 (45). 
A double-blind randomised controlled trial reported ondansetron to be superior to 
doxylamine in combination with pyridoxine for the management of NVP (198). 
However, this study did not use the delayed release form, and it used half the 
recommended dose of the doxylamine-pyridoxine combination, which may have 
favoured ondansetron (199). Another randomised controlled trial found that ondansetron 
and metoclopramide have similar effects on NVP (177). 
The recommended dosage of ondansetron in the Norwegian guidelines is 4–8 mg two 
times daily as tablets, or 4 mg two times daily administered as an intramuscular injection 
(34). 
Common side effects are headaches, constipation and drowsiness (31, 188). Serotonin 
syndrome is a possible side effect of ondansetron if combined with other medicines 
affecting serotonin levels, such as selective serotonin reuptake inhibitors (31, 193). The 
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FDA raised concerns in 2011 suggesting that ondansetron could cause QT prolongation, 
which can lead to Torsade de Pointes (200). Electrocardiogram (ECG) monitoring is 
therefore advised in patients with electrolyte abnormalities, which will include many 
patients presenting with severe NVP/HG (193). 
Glucocorticoids 
It has been known for more than 30 years that corticosteroids are effective against 
chemotherapy-induced nausea and vomiting (115), and they are also mentioned in most 
guidelines for NVP (27, 29-35). The mechanism of action is elusive, and there is 
conflicting evidence with respect to their effectiveness against NVP (31, 201, 202). 
Ideally, glucocorticoids should only be used after pregnancy week 10 due to associations 
between glucocorticoid use and a slightly increased risk of oral clefts when administered 
before this time point in pregnancy (203-206). They are therefore referred to as last line 
treatment, and it is recommended that they be reserved for refractory cases of NVP (27, 
29-32, 34, 35). 
 1.7.4 Intravenous hydration and enteral and parenteral nutrition 
Patients who are dehydrated and unable to maintain adequate normal electrolyte levels 
should be rehydrated with intravenous fluid containing the appropriate electrolytes and 
vitamins (31). It is important to delay glucose infusion until after thiamine has been 
administered due to concerns about Wernicke’s encephalopathy (34).   
Refractory patients not responding to pharmacological interventions and who have 
weight loss are assessed for enteral or parenteral nutrition (31, 34). Enteral nutrition 
(nasogastric or nasojejunal tube feeding) is preferred to parenteral nutrition since total 
parenteral nutrition requires a central venous access device that is associated with 
increased risk of serious complications, such as infections or thrombosis (31, 34, 207). 
However, partial parenteral nutrition can be administered via a peripheral vein over a 
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short time period in conjunction with the correction of fluid and electrolyte disturbances, 
or upon initiating nasogastric or nasojejunal tube feeding (34).   
 1.7.5 Adjunct therapies 
Antacids 
Heartburn and reflux symptoms are very common in pregnancy, affecting 40–85% of 
pregnant women, and have been found to be associated with increased severity of NVP 
(155). Moreover, adding antacids to the existing antiemetic regimen has resulted in a 
reduction in NVP severity (208). Consequently, women who experience symptoms such 
as burping, belching, nausea at night, burning, indigestion or feelings of a lump at the 
back of the throat may find relief in recommendations that focus on decreasing acid 
symptoms, such as avoiding high fat or fried foods, sleeping in an elevated position or 
adding antacids therapy as needed (45). The antacid recommended in the Norwegian 
guidelines is omeprazole 20 mg once daily (34). UpToDate recommends H2-receptor 
antagonists, such as ranitidine, for heartburn and reflux symptoms (31). H2-receptor 
antagonists and proton pump inhibitors have been investigated for their safety when used 
during pregnancy, with reassuring results (209, 210).   
A summary of the treatment recommendations described above is shown below in form 




Figure 3. Treatment algorithm for NVP. Adapted from the Norwegian guidelines issued by 
NGF, UpToDate, Motherisk and the Danish HG guidelines issued by the Danish Society for 
Obstetrics and Gynaecology (29, 31, 34, 163).  
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 1.7.6 Counselling and emotional support 
The Canadian guidelines suggest that support and understanding from close friends and 
family, and also supportive counselling, may be beneficial for women suffering from 
NVP (30, 45). One study found a positive association between NVP and stress, and an 
inverse relationship between stress and social support, indicating that severe NVP 
associated with perceived stress levels may be mediated by social support (211). Having 
high social support has been found to be associated with lower severity of NVP (79). 
Telephone counselling had a positive effect on perceived social support among women 
with NVP (212). Moreover, a study investigating the impact of professional support, 
such as including individualised health education and supportive phone calls about NVP, 
found that the intervention group had significantly lower severity of NVP and perceived 
level of symptom distress, while showing an improvement in quality of life, when 
compared to the control group (213).  
The importance of taking a woman presenting with NVP seriously has been stressed by 
several authors (95, 214-217). A high level of patient satisfaction has been associated 
with women’s perceptions that physicians believed in their descriptions of their 
symptoms (215). A low level of belief in the women’s description of the severity of 
symptoms may result in delayed intervention, and can thereby affect the time required 
for recovery (215). This experienced lack of understanding of NVP among healthcare 
personnel was also reported by Locock et al. (216).  
 1.8 Prevalence of treatment of NVP 
Estimating the prevalence of treatment of NVP in prior studies is challenging due to a 
wide range of definitions of NVP treatment. Treatment of NVP includes both 
prescription medicines and over-the-counter (OTC) medicines as well as CAM, and the 
medicines used are not restricted to one ATC class, which means that drug utilisation in 
pregnancy studies in general seldom provide data on this.  
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Studies are available from various countries, but the data sources used vary and the study 
designs have been based on different populations, see Table 3. Studies report the 
proportion of women taking one or more antiemetic medicines, ranging from 1–3% in 
the UK, to 14–61% in Canada, with 3% in the Netherlands, 5% in Sweden, 5–10% in 
Italy, 11–15% in the USA, 11% in Germany, 15%–21% in France, and 26% in Australia 
in between (52-54, 94, 166, 197, 218-222), see Table 3. However, direct comparison is 
impossible with such large differences in methodology.  
The same challenge applies when considering CAM used against nausea. In addition to a 
variety of methodologies used, different therapies have been included in the definition of 
CAM. The proportion of women using non-pharmacological therapies for NVP has been 
reported to be 1.5% (herbs) / 2.1% (homeopathy) in Germany, 42% in Australia and 18–
69% in Canada (52, 54, 94, 219, 223, 224), see Table 3.  
Though not specifically reporting prevalence of NVP treatment, two comparative studies 
of interest is found of which both are indicating a presence of intercountry variations of 
type and prevalence of NVP treatment. In 1998 an informal survey enquiring about 1st, 
2nd and 3rd choice treatment for NVP was conducted in several European countries (225). 
This study detected wide variations in the types of treatment used against mild and 
moderate nausea and vomiting, whereas hyperemesis gravidarum was treated quite 
similarly in the vast majority of countries (225). Another study among women having 
experienced HG found intercountry variations of frequency of different treatments used 
against this illness (226). However, in conclusion we have little knowledge about 
differences in NVP treatments, i.e. conventional and herbal medicines, across countries, 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 1.9 Methodological aspects  
 1.9.1 Pharmacoepidemiology 
The medications market is constantly changing. Each year new medicines are 
marketed, while others are withdrawn and medicines previously only available on 
prescription become available OTC. Guidelines for the specific disorders may also 
change. Drug utilisation studies are therefore needed to understand how drugs are 
used in a defined population, time trends of use and how various factors influence 
use. Drug utilisation is defined by the World Health Organization (WHO) as ‘the 
marketing, distribution, prescription, and use of drugs in a society, with special 
emphasis on the resulting medical, social and economic consequences’ (227). Drug 
utilisation research can be divided into descriptive and analytical studies, and it is an 
essential part of pharmacoepidemiology, since it describes the extent, nature and 
determinants of drug exposure (227). The findings from drug utilisation studies form 
the basis for analytical pharmacoepidemiological studies (227).  
Pharmacoepidemiology has been described as ‘the study of the use of and the effects 
of drugs in large numbers of people’ (228). It is a research field linking clinical 
pharmacology and epidemiology (228). The field borrows its focus of inquiry from 
clinical pharmacology and its methods of inquiry from epidemiology (228).   
Since pregnant women are generally excluded from clinical trials due to ethical 
considerations and concerns about potential teratogenic effects, epidemiological 
methods are necessary to gather and evaluate information about the population 
actually using a drug in order to examine its safety of use during pregnancy (228).  
Various types of observational epidemiological study designs exist that can be 
classified as descriptive or analytical (228). An observational study design refers to 
case reports, case series, analyses of secular trends, case-control studies and cohort 
studies (228). Case reports, case series and analyses of secular trends are referred to 
as descriptive studies, while case-control studies and cohort studies are referred to as 
analytical studies (228). Cohort studies and case control studies represent the two 
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main types of epidemiological studies (229). These studies provide information about 
the extent of the association between exposures during pregnancy and the outcomes. 
They are ‘analytical’ in their ability to determine measures of association, and can be 
of a retrospective or prospective design (228). Cohort studies are known as the 
archetype of epidemiological studies and involve measuring disease within one or 
more cohorts (229). This design has many advantages, such as enabling incidence 
rates or risks to be calculated (229). Cohort studies are useful when studying many 
outcomes and uncommon exposures (228). The exposure data are unbiased, and 
selection bias is less likely (228). However, cohort studies are not suitable for rare 
outcomes, they are usually expensive and can take years to complete (228). 
Furthermore, outcome data may be biased (228). 
Cross-sectional studies collect data at a single time point and provide snapshots of the 
population status with respect to disease or exposure status (229). This design 
provides rapid answers, and data on all variables are collected once. Multiple 
outcomes and exposures can be studied, and prevalence estimates can be obtained 
(229). However, since risk or rate calculations require information across a time 
period, a cross-sectional study cannot measure disease incidence, and it cannot 
provide information about causes of disease (229). Nevertheless, cross-sectional 
studies are useful for descriptive analyses and for raising hypotheses, and for 
shedding light on problems related to the use of medicines in the population.  
 1.9.2 Qualitative research design 
The social world in the healthcare sector cannot be solely explained by numbers, 
which may explain the growing interest in qualitative methods among healthcare 
researchers in recent decades (230). While quantitative research primarily involves 
numbers, qualitative research focuses on the meanings that are attached to people’s 
experiences of the social world and how that world makes sense to them (230). 
Qualitative studies are typically used to answer ‘why’ and ‘how’ questions, and to 
explore processes and patterns in people’s thoughts and behaviour (231). Quantitative 
and qualitative approaches complement each other and are increasingly being used 
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together and in parallel in health research (230). Qualitative research can also be 
helpful in validating quantitative research results, by providing a different perspective 
on the studied social phenomena, providing insight to aid the interpretation or 
understanding of quantitative data, and/or to explain relationships between variables 
(230, 231). And vice versa, quantitative research can also be used to follow up 
qualitative research by quantifying the findings of a qualitative study (230). 
 
Various qualitative research methods exist, including direct observation, interviews 
and text or document analysis (230), of which interviews are most commonly 
employed in health research (231). Interviews can be conducted as face-to-face 
interviews with individual respondents or with a group (e.g. focus groups), according 
to an unstructured, a semi-structured or a structured interview guide (231). It is 
important that the research design is appropriate to the research question (232). 
 
High quality is also striven for in qualitative research. However, the well-known 
criteria used to assess the quality of quantitative research – reliability and validity – 
seem to have an uncertain place in qualitative research (233). The philosophical 
beliefs underpinning quantitative and qualitative methodologies are traditionally 
based on different ontologies (232). Hence the criteria applied in quantitative research 
to assess quality cannot easily be transferred to and applied in a qualitative research 
setting (232). The general ontological assumption among qualitative researchers is 
that reality is dynamic, contextual, socially constructed and dependent of time and 
place. This implies that, in order to study the social world, other more suited 
theoretical perspectives and methods are needed (232). Though there is agreement 
that a rigorous application of the principles of qualitative methodology must be 
striven for at all stages of the research process, there is still an ongoing debate among 
qualitative researchers on how to handle the traditional concepts of reliability and 
validity, as well as what criteria to apply when evaluating qualitative research (232, 
233). While some believe that reliability and validity should be standards for 
assessing the quality of qualitative research, this is rejected by others who argue that 
other terms or concepts are needed (232-234). Denzin and Lincoln suggest replacing 
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the traditional criteria of internal and external validity, reliability and objectivity with 
the terms credibility, transferability, dependability and confirmability (see Box 2) 
(232, 233).  
 
Box 2. Commonly applied criteria to assess the quality of quantitative and qualitative 
research. Adopted from Devers (232). 
Quantitative research Qualitative research 
Internal validity: The degree to which the 
findings correctly map the studied 
phenomenon. 
Credibility: The ‘truth’ of the findings, as 
perceived by the participants and within the 
context in which the research is carried out. 
External validity: The extent to which the 
results can be generalised to other settings 
similar to the one in which the study was 
conducted. 
Transferability: The extent to which the 
findings generated are 
applicable/transferable to other settings with 
a similar context.  
Reliability: The degree to which the findings 
can be replicated by another researcher. 
Dependability: The extent to which the 
research would produce similar or consistent 
findings if carried out as described. 
Objectivity: The extent to which the findings 
are free from bias. 
Confirmability: Evidence that verifies the 
findings must be provided by the researcher. 
 
To conclude, findings from qualitative studies have limitations with respect to the 
quantitative concept of ‘generalisability’. However, the objectives of qualitative 
research are, as stated above, more to explore and explain in-depth various 
phenomena than to test the extent to which characteristics apply to a large population 
(218). To summarise, regardless of qualitative and/or quantitative tradition, an open 
and detailed description of the research process is important for the reader to be able 
to assess the quality of the research results. 
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 Aims of the studies 2.
The overall aim of this research project was to explore various aspects of treatment of 
NVP with special focus on attitudes to and use of pharmacological treatment. The 
specific aims of each study were: 
Paper I 
The primary aim of this study was to investigate whether exposure to ginger was 
associated with an increased risk of congenital malformations. The secondary aim 
was to investigate the effects of ginger use on vaginal bleeding, stillbirth/perinatal 
death, birth weight, preterm birth and Apgar score. 
Paper II 
This study aimed to describe differences in self-reported nausea during pregnancy, as 
well as the patterns of use of both conventional and herbal medicine across countries 
in Western, Northern and Eastern Europe, North America, and Australia. The study 
also aimed to investigate factors related to nausea and its treatment, as well as the 
relationships between different self-reported comorbidities and nausea.   
Paper III 
The aim of this study was to explore thoughts and attitudes among Norwegian 
pregnant women and GPs about the treatment of NVP, and to identify potential 
barriers to optimal care for women with NVP.  
Paper IV 
In aim of this study was to investigate the treatments used for NVP according to NVP 
severity defined by the PUQE scale among women in Norway. A secondary aim was 
to assess whether maternal characteristics and attitudes were related to the use of 
pharmacological treatment of NVP. 
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 Material and methods 3.
Design, setting and participants 
Table 4 provides an overview of the design, setting and participants in the studies that 
are included in the thesis. A brief description of each study follows below. For further 
details, please see Paper I−IV. 
Table 4. Overview of the studies that are included in the thesis and their characteristics. 




Norway  Norwegian pregnant women were recruited at 17-18 






Pregnant women and new mothers with a child <1 






Pregnant women were recruited when attending 
routine ultrasound examinations, n = 10. 
General practitioners under specialisation were 
recruited through contacting supervisors of the 




Norway Pregnant women or new mother with a child <1 year 
of age who had experienced NVP, n = 712. 
 3.1  Paper I The MoBa study: Safety of ginger use in 
pregnancy 
 3.1.1 Data sources 
The Norwegian Mother and Child Cohort Study 
The Norwegian Mother and Child Cohort study (MoBa) is a population-based cohort 
study conducted by the Norwegian Institute of Public Health, which recruited 
pregnant women in Norway between 1999 and 2008 (235, 236). The aim of the study 
is to identify causes of serious diseases in mothers and children (235). Participants 
were recruited by postal invitation received together with the routine ultrasound 
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examination offered to all pregnant women in Norway in pregnancy week 17–18. An 
information brochure, an informed consent form, and the first questionnaire were 
enclosed with the invitation (235). The recruitment started in the county of Hordaland 
in Western Norway in 1999, and expanded gradually to include 50 out of 52 hospitals 
in Norway with more than 100 births annually. In 40.6% of the pregnancies, the 
women agreed to participate. The last child in the cohort was born in 2009. The 
cohort now includes more than 90,000 pregnancies and 100,000 children from all 
over Norway, and the children are still followed (237). 
Self-administered questionnaires form the basis for the study. The participants 
completed two self-administered questionnaires during pregnancy, and one 
questionnaire when the child was six months old, providing information relevant to 
this study (238-240). The women completed an additional questionnaire at pregnancy 
week 22 that covered dietary information (241), but this questionnaire was not used 
in this study. The first questionnaire was completed during pregnancy weeks 13-17 
and covered the period from six months prior to pregnancy until completion. The 
second questionnaire was completed at pregnancy week 30. The third questionnaire 
was distributed when the child was six months old, providing information on the last 
part of pregnancy. The self-administered questionnaires provide information about 
sociodemographic characteristics, outcomes of previous pregnancies, medical history, 
maternal health, lifestyle habits, drug exposure and other exposures during 
pregnancy. 
The Medical Birth Registry of Norway 
The Medical Birth Registry of Norway (MBRN), established in 1967, is based on 
compulsory notification of all live births, still births and induced abortions after 
gestational week 12 (after gestational week 16 up to 2002), and encompasses all 
births in Norway (242, 243). The notification form includes information about 
maternal health prior to and during pregnancy, medicine use during pregnancy, birth 
complications and interventions, postpartum complications, and the health of the 
neonate (243-245). Diagnoses are coded according to the International Statistical 
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Classification of Disease (ICD) and related health problems and unique codes 
developed by the MBRN (43, 246). 
 3.1.2 Study population 
 
Figure 4. Flow chart of study population included in the study in Paper I. 
 
The MoBa quality-assured data file released for research, version 4, was used in this 
study. Women who both have a record in MBRN and had answered the first 
questionnaire were included in the study. Women who gave birth to multiples or to 
children with chromosomal malformations were excluded. Hence, the final study 
population included 68,522 women and their infants.   
 3.1.3 Measures  
Information about ginger use was retrieved from the three MoBa questionnaires (238-
240). Several indications were mentioned in the questionnaires and, for each 
indication mentioned, it was possible for the women to specify several products used 
for the complaint. Additionally, the women could report the use of supplements and 
herbal products in response to specific questions about such use. The use of herbal 
products was reported as names of products in free text fields. The research team 
Women having completed Q1 and 
MBRN record 
69,930 
n = 68,522 
Multiparous (parity ≥ 2) 
women,  
n = 1,291 (1.8 %) 
Women who gave birth to children 
with chromosomal  
malformations 
n = 121 (0.2%) 
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systematically reviewed all medicine text fields and text fields for dietary 
supplements/herbal remedies in the three questionnaires for herbal products. All 
identified herbal products were systematically coded according to a pre-determined 
herbal classification list based on the herbal ingredient(s). This classification system 
was developed by the research team and included the common name of the herb and a 
seven-character specific code to facilitate standardisation of the coding in the 
questionnaire database. This work took the research team more than a year and 
included 1) sorting each text field by product/herbal name in descending order to 
make sure that no herbal product was missed, and 2) creating a classification list and 
making sure that the individuals involved coded the herbals in the same way.  
Information about outcome variables was retrieved from MBRN, with the exception 
of information about maternal vaginal bleeding, which was self-reported and 
retrieved from MoBa. We investigated all malformations as defined by the MBRN, 
which follows the European Surveillance of Congenital Anomalies’ (EUROCAT) 
classification system of congenital anomalies (246, 247). Malformations were 
classified as all malformations, major malformations and cardiovascular 
malformations. A patent ductus arteriosus (ICD-10 code Q25.0) in premature infants 
was not considered a cardiovascular malformation (43). We also investigated the 
following adverse pregnancy outcomes: stillbirths and perinatal deaths, low birth 
weight, preterm birth, and low Apgar score at five minutes after birth.  
The detailed nature of the MoBa questionnaires in combination with information 
from MBRN provided information on a wide range of potential confounding factors.  
 3.1.4 Statistical analyses 
Pearson’s chi-square test was applied to test for associations between ginger use and 
maternal characteristics or variables related to maternal illness. A p-value <0.05 was 
considered significant. To investigate the risk of malformations and selected 
pregnancy outcomes associated with ginger use, univariate and multivariable logistic 
regression analyses were used to obtain crude and adjusted odds ratios (ORs), 
respectively. Statistically or clinically significant variables were explored for each 
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pregnancy outcome. The selection of variables to be included in the potential 
confounder sets was based on theoretically potential influences, as well as the results 
from exploratory data analysis. Maternal age, parity, pre-pregnancy body mass index 
(BMI), folic acid use, smoking, education, NVP, previous miscarriages/stillbirths, 
year of delivery, and infant sex were considered possible confounders, and adjusted 
for when estimating the risk of malformations and preterm birth. The remaining 
selected pregnancy outcomes were also adjusted for by length of gestation. 
 3.1.5 Ethics 
The MoBa study was approved by the Regional Committee for Ethics in Medical 
Research, Region South, and the Norwegian Data Inspectorate.  
 3.2  Paper II The multinational web-based cross-sectional 
study: Treatment of NVP 
 3.2.1 Data source and study population 
The multinational cross-sectional study among pregnant women and 
new mothers 
Paper II was a sub-study using data from a web-based, cross-sectional study carried 
out in 18 countries simultaneously. An online self-completed questionnaire was 
available for two months in each participating country between 1 October 2011 and 
29 February 2012. The national coordinators in each of the participating countries 
chose relevant, commonly visited pregnancy and baby-related websites on which an 
advert containing a link to the questionnaire was posted (15). The questionnaire was 
originally developed in English and Norwegian, and was translated into the relevant 
languages. The quality, comprehension and adaptation of the translated questionnaire 
to the relevant national context were assured by the national coordinator in each 
participating country. Women who were pregnant or who had a child of <1 year of 
age could participate in the study.  
In order to assess the representativeness of the study population, the 
sociodemographic and lifestyle characteristics (i.e. age, marital status, education and 
 64 
smoking) of the study population were compared to the general birthing population in 
the corresponding country. The similarities were satisfactory, with the exception that 
the study participants were generally more educated than the general birthing 
population (15). In specific countries (Australia, Canada, France, the Netherlands, 
Russia and the USA), the study sample constituted a small proportion of the general 
birthing population (15).  
The original data file comprised 9,459 women from the 18 participating countries 
who completed the online questionnaire, including 346 women from various 
countries in South America who accessed the questionnaire via North American 
websites. The women from South America were omitted due to a risk of being a 
biased group. Hence, the final study population consisted of 9,113 women.  
 3.2.2 Measures 
Information about self-reported nausea and other health disorders/short-term illnesses 
during pregnancy was available from the questionnaire, together with information 
about treatments used for these complaints. Standardised questions about OTC use 
were also posed to the women, as well as questions about herbal medicine use during 
pregnancy. Medicines were defined as single products containing one or more active 
ingredients, and were coded into the corresponding ATC codes according to the 
WHO ATC index (173). Supplements such as vitamins, minerals and CAM, were 
distinguished from medicines and coded separately.  
Symptoms of depression were measured by the Edinburgh Postnatal Depression Scale 
(EPDS). This is a self-rating scale consisting of ten items, developed by Cox et al. to 
detect postnatal depression (248). Though it was initially developed to detect 
postnatal depression, the scale has also been validated as a screening tool for major 
depression in pregnant women with satisfactory results, and it has been used in 
several studies worldwide (249, 250). Cut-off scores of 11, 10 and 10 applied at 
weeks 12, 24 and 36 of pregnancy, respectively, resulted in 79%, 70% and 76% 
sensitivity, respectively, and 97%, 96% and 94% specificity, respectively (250). The 
scale rates the intensity of depressive symptoms over the previous seven days, and 
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each item is scored 0, 1, 2 or 3, resulting in a total score range between 0 and 30. 
Validated translated versions of the original EPDS were available in Dutch, French, 
German, Icelandic, Norwegian, Slovenian, Spanish and Swedish (249). For the 
remaining languages, translated versions used in previous studies were applied (251-
254), except for the Slovenian version, which was developed by two independent 
linguistic experts. We used a cut-off of ≥13. 
 In addition, detailed information about maternal sociodemographic and lifestyle 
habits was retrievable from the questionnaire.  
 3.2.3 Statistical analyses 
Descriptive statistics were used to calculate the prevalence of conventional and herbal 
medicine use against nausea during pregnancy. Univariate and multivariable 
generalised estimating equation (GEE) analyses were used to explore potential 
significant associations between maternal characteristics and the use of conventional 
medicines against nausea, and between comorbidity and nausea and its treatment. The 
GEE with the binary logistic model was applied to correct for clustering on region of 
residency. Crude and adjusted ORs are presented with 95% confidence intervals. 
Reduced models were fit by excluding non-significant variables unless removal of the 
variable caused a >10% change in the effect estimate. 
 3.2.4 Ethics 
The study was approved by the Regional Ethics Committee, Region South-East in 
Norway. In addition it was notified to and approved by each of the relevant national 
Ethics Boards when required by national legislation. Answering ‘Yes’ to the question 
‘Are you willing to participate in the study?’ after having been shown the study 
description was regarded as giving informed consent. 
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 3.3 Paper III The focus group discussion: Attitudes to and 
thoughts on treatment of NVP among pregnant women 
and general practitioners 
 3.3.1 Study population 
Women attending a routine ultrasound examination in pregnancy week 17–18 at 
Kvinneklinikken, Haukeland University Hospital, and who had experienced NVP 
during their current pregnancy, were handed an information brochure that included an 
invitation to participate in a study by healthcare professionals working at the clinic. 
The information pamphlet contained information about the study as well as contact 
details for the research group. The women were kindly asked to get in touch if they 
had any questions or were interested in participating in the study. Due to slow 
recruitment, the snowball recruitment method was also applied. In total, 10 pregnant 
women were recruited and grouped into two focus groups of four and six participants, 
respectively.  
Educational groups for GPs under specialisation in general practice were contacted 
by e-mail with the aim of recruiting GPs to the study. Two focus group discussions 
were carried out with five GPs in each group.  
 3.3.2 Measures/information 
The women and the GPs were asked to tell about their own thoughts and experiences 
of treatment of NVP. Elements included in the interview guides are shown in Table 5. 
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Table 5. Elements included in the interview guides. 
Pregnant women General practitioners 
Experience of NVP Thoughts about treatment 
Different aspects of treatment 
Important concepts in the care of 
pregnant women with NVP 
- Where to seek advice The question of treatment 
 The question of treatment  Thoughts about treatment 
 Thoughts about dietary and lifestyle 
changes 
 Thoughts about dietary and 
lifestyle changes 
 Thoughts about medicines  Thoughts about medicines 
 Thoughts about alternative 
treatments 
 Thoughts about alternative 
treatments 
 
 3.3.3 Data collection 
Data collection was carried out as part of two master’s projects. Two separate 
interview guides of a semi-structured nature containing open-ended questions were 
developed for the focus group discussions with the women and the GPs. The focus 
group discussions were audio-recorded and moderated by the master’s student, who 
also transcribed the audio-recordings verbatim with one exception; in this case the 
role of the moderator was filled by the student’s supervisor, who quality-checked the 
verbatim transcription. The PhD student acted as secretary. 
The focus group discussions lasted approximately 60 minutes each.  
 3.3.4 Analysis 
The transcripts from the focus group discussions with the GPs and the pregnant 
women were analysed separately, and according to the principles of systematic text 
condensation as described by Malterud (255). Firstly, to establish an overview of 
data, the transcripts were read as a whole by three of the members of the research 
team who had also been present at the focus group discussions. Secondly, preliminary 
themes, representing different aspects of the participants’ thoughts on and attitudes to 
treatment of NVP were identified by each member of the research team individually. 
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The members of the research team then met, and agreed on themes or code groups 
through collaborative negotiation. Thirdly, meaning units (a text fragment that 
contains information about the research question) were sorted under the appropriate 
themes or code groups. The content of the coded groups was then reduced to a 
condensate that aimed to capture the essence of the meaning units. Lastly, 
descriptions and concepts were developed based on the condensates.  
 3.3.5 Ethics 
The study was approved by the Regional Committee for Ethics in Medical Research, 
Region West, and the Norwegian Data Inspectorate. 
 3.4 Paper IV The Norwegian web-based cross-sectional 
study: Treatment of NVP 
 3.4.1 Data source and study population 
The EMESIS study 
This study is based on a cross-sectional study that collected data through an online 
questionnaire accessible from 10 November 2014 to 31 January 2015. A link to the 
questionnaire was posted on websites and social networks commonly visited and 
consulted by pregnant women and/or new mothers. It was also accessible via the 
study’s own Facebook page. A pilot study was carried out (n=5), resulting in only 
minor changes to the questionnaire. Collected data were scrutinised to uncover 
potential duplicates (based on sociodemographic data), without detecting any.  
Women who were pregnant or who had a child of <1 year of age, and who had 
experienced NVP in their latest pregnancy, were eligible to participate.  
 3.4.2 Measures 
The questionnaire provided data on maternal characteristics, NVP and treatments 
used for NVP, such as conventional medicines, CAM and hospitalisation. The 
questionnaire also included questions on the women’s beliefs about medicines and 
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alternative treatments. A list of commonly used therapies was presented to the 
women, who were asked to report the therapy used, duration of therapy, dosage and 
who initiated the treatment. 
The PUQE scale was used to measure symptoms of NVP and classify the women into 
three groups according to the severity of their symptoms (44). They were asked to 
report on the extent of their NVP during a typical 24 hours in the period with the 
most severe symptoms. PUQE consists of three items assessing the severity of 
symptoms; the numbers of hours of nausea, the number of episodes of retching and 
the number of episodes of vomiting within the last 24 hours (see Box 3). Each item is 
scored from 1 to 5 points. The PUQE score is calculated by adding the values from 
each category, resulting in a total score ranging from 3 to 15 points. A score of ≤ 6 
points is classified as mild NVP, 7–12 points as moderate and a score ≥ 13 as severe. 
PUQE has been validated to correlate with the following factors: risk of 
hospitalisation due to severe NVP, insufficient nutritional intake, inability to take iron 
supplements, and reduced well-being/quality of life (256, 257). PUQE was recently 
translated into and validated in Norwegian (257). 
Box 3. The 24-hour Pregnancy-Unique Quantification of Emesis scale (PUQE-24). Adapted 
from Ebrahimi et al. (44). 
Motherisk PUQE-24 scoring system 
In the last 24 hours, for how 
long have you felt nauseated or 
sick to your stomach? 
Not at all 
 
(1) 









More than 6 
hours 
(5) 
In the last 24 hours have you 
vomited or thrown up? 












I did not 
throw up 
(1) 
In the last 24 hours how many 
times have you had retching or 














7 or more 
times 
(5) 
PUQE-24 score: Mild ≤6; Moderate: 7-12; Severe ≥13 
How many hours have you slept out of 24 hours? Why?_____________________________ 
On a scale of 0 to 10, how would you rate your well-being?__________________________ 
0 (worst possible), 10 (the best you felt before pregnancy) 
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 3.4.3 Statistical analyses 
Univariate and multivariable logistic regression analyses were performed to explore 
potentially significant associations between maternal characteristics and the use of 
conventional medicines for NVP. Reduced models were fitted by excluding non-
significant variables, unless removal of the variable caused a >10% change in the 
effect estimates. 
 3.4.4 Ethics 
The participants were presented the study description before completing the 
questionnaire. If the woman answered ‘Yes’ to the question ‘Are you willing to 
participate in the study?’ this was regarded as giving informed consent. The study 
was approved by the Regional Committee for Ethics in Medical Research, Region 
West, and the Norwegian Data Inspectorate. 
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 Summary of results 4.
 4.1 Paper I The MoBa study: Safety of ginger use in 
pregnancy 
In total, 68,522 women were included in the study, of whom 1,020 (1.5%) reported 
using ginger during pregnancy. We found that 466 women (45.7%) used ginger 
during the first trimester. NVP was the most frequently reported indication for the use 
of ginger.  
Though women who used ginger during pregnancy were more likely to have 
experienced vaginal bleeding after week 17 than controls, when the analyses were 
restricted to vaginal bleeding more than spotting, neither crude nor adjusted ORs 
revealed a significant association. No association was found between ginger use and 
vaginal bleeding before week 17.  
Use of ginger during the first trimester of pregnancy or at any time during pregnancy 
was not associated with an increased risk of malformations in general, major 
malformations, or cardiac malformations, neither according to crude nor adjusted 
analyses (Figure 5). In addition, no significant associations were detected between the 
use of ginger during pregnancy and a risk of stillbirth/perinatal death, low birth 
weight, preterm birth, or low Apgar score in univariate analyses or after adjustments 
were made (Figure 5). Adjusted ORs are shown in Figure 5. 
The following maternal characteristics were associated with the use of ginger: a 
higher level of education, non-smoking and use of folic acid before and during or 
only during pregnancy. Compared to the women who did not use ginger, use of 
ginger was also associated with having experienced any NVP, having been 
hospitalised during pregnancy due to prolonged NVP, having had NVP during a 
previous pregnancy, having been on sick leave during pregnancy, and having given 









 4.1.1 Additional sub-analyses of risk of vaginal bleeding stratified 
by timing of ginger use 
The previous analyses on vaginal bleeding and ginger were not stratified by timing of 
use. Additional sub-analyses are therefore presented in this section. The results of the 
analyses after stratification by timing of use did not reveal any significant increased 
risk of vaginal bleeding (unpublished, see Table 6). Adjustments were made for NVP, 
maternal age, parity, maternal pre-pregnancy BMI, maternal smoking, folic acid use, 
pervious miscarriages, physical activity and education. 
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before week 17 
13,255 (19.3) 167 (20.0)  
 
1.0 (0.9-1.2) 0.9 (0.7-1.1) 
Hospitalised due to 
bleeding before 
week 17  













Vaginal bleeding in 
week 17 and after 
4,027 (5.9) 23 (7.5)  1.3 (0.9-2.0) 1.4 (0.9-2.2) 
Vaginal bleeding in 
week 17 and after, 
more than spotting 
1,430 (2.1) 9 (3.0)  1.4 (0.7-2.8) 1.7 (0.9-3.3) 
Hospitalised due to 
bleeding in week 
17 and after  
362 (0.5) 2 (0.7)  1.2 (0.3-5.0) 1.5 (0.4-6.3) 
 
 4.2 Paper II The multinational web-based cross-sectional 
study: Treatment of NVP 
Altogether, 9,113 women were included in the study, the majority of whom were 
residents of Europe (Western, n=3,201; Northern, n=2,820; Eastern, n=2,342), 
followed by North America (n=533) and Australia (n=217).  A total of 6,701 (73.5%) 
had experienced nausea during pregnancy. Among respondents with nausea, 
conventional medicines were used by 1,201 (17.9%) women and herbal medicines by 
556 (8.3%) women. The extent of self-reported nausea and its treatment showed 
geographical variation. Use of treatment of nausea among women experiencing 
nausea by country of residence is shown in Figure 6. 
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Figure 6. Use of treatment against nausea among women experiencing nausea by region 
of residence. 
 
The prevalence of nausea was lowest in Russia (62.0%) and highest in Iceland 
(84.5%). The proportion of women using any antiemetic among those with nausea 
was highest in Canada, France, Sweden and Switzerland. In the majority of the 
countries, the most commonly used medicines were antihistamines or 
metoclopramide, except for in the USA (ondansetron) and Russia, Serbia, Croatia and 
Slovenia (antacids). The most commonly used herbal medicine in the vast majority of 
countries was ginger. Education, working status and folic acid use were significantly 
associated with the use of medicines for nausea. Women who reported nausea 
reported having comorbidities significantly more often, especially heartburn.   
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 4.3 Paper III The focus group discussion: Attitudes to and 
thoughts on treatment of NVP among pregnant women 
and general practitioners 
Two focus group discussions were held with pregnant women and two with GPs in 
Norway. Both groups of participants elaborated on several aspects of nausea and 
pregnancy care. The GPs expressed that it was important to normalise symptoms of 
NVP. However, the women felt that the GPs trivialised their distress due to NVP, 
implying that the pregnant women and the GPs seemed to talk at cross purposes. The 
women missed acceptance and acknowledgment from their GP of how debilitating 
NVP is to live with. Moreover, the women missed being evaluated properly for the 
severity of their NVP symptoms. The GPs had a wish for an objective instrument to 
measure symptom severity.  
Though the women had cried out for help due to great distress, they were sceptical 
about using medicines while pregnant and tried to avoid such use despite being ill. 
However, the women made it clear that they realised that the choice of treatment was 
individual and respected others for using any. The choice of treatment seemed to 
depend on how much one could bear of the negative impact caused by the NVP 
symptoms. The GPs seemed to be unsure about how to treat NVP when dietary and 
lifestyle interventions were insufficient. Though medicines were considered to be the 
next step, the overall attitude among the GPs was to avoid medicines against NVP, 
mainly due to fear of teratogenicity. Referrals to the thalidomide tragedy were made 
by both the GPs and the women. The GPs wanted a medicine with NVP as approved 
indication. A general lack of belief in the effectiveness of the medicines used for 
NVP was expressed by some of them. Sick leave seemed to be an important part of 
the treatment regime applied by the GPs, but was also presented as a dilemma with 
the Norwegian Labour and Welfare administration’s strict policy on one side and the 
pregnant women’s begging on the other side. The women had good experience of 
graded sick leave. 
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 4.4 Paper IV The Norwegian web-based cross-sectional 
study: Treatment of NVP 
Altogether, 712 women in Norway were included in the study. According to the 
PUQE classification, 62 (8.7%), 439 (61.7%) and 210 (29.5%) had mild, moderate 
and severe NVP, respectively. A total of 277 (38.9%) women had used one or more 
antiemetics, 384 (53.9%) women had used CAM, and 188 women had used both 
conventional medicines and CAM. Severity of symptoms, education and work 
situation were factors associated with the use of medicines for NVP. The most 
commonly used medicine was meclizine, closely followed by metoclopramide. The 
majority of the women using medicines (60.6%) had only used one medicine, 
although the maximum number of medicines used was six. Among the women who 
had only used one medicine, only 53.5% had used an antihistamine, which is 
recommended as first line treatment for NVP. This implies that guidelines are not 
consistently followed. Ginger and acupressure were the most commonly used types of 
CAM, which is in accordance with recommendations made in the guidelines. 
Different drug utilisation patterns were found between the groups of women with 
different severity of NVP, showing a gradient towards higher use of all medicines for 
NVP with increasing severity. Nonetheless, many with moderate and severe 
symptoms did not receive any pharmacological treatment (70.2% and 32.9%, 
respectively). Of the women who had been on sick leave due to NVP, sick leave was 
prescribed without initiating medical treatment for 266 (62.1%) women, and only 37 
(8.6%) women started medical treatment before they went on sick leave.  
The women’s beliefs about medicines had an important impact on their use of 
medicines for NVP. Women who agreed with or were uncertain about the statement 
‘It is better for the foetus that I use medicines and get well than to have an untreated 
illness during pregnancy’ were more likely to have used medicines than women who 
disagreed. In total 79.4% reported that they had a higher threshold for using 
medicines while pregnant, and only 29.6% believed that the foetus would benefit 
from the mother taking a medicine to get well. Severity of symptoms was associated 
with the women’s beliefs. 
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 Discussion 5.
 5.1 Main findings 
Several of our findings provide new knowledge about attitudes to and the treatment 
of NVP. The most important findings from a clinical perspective are: 
The extent of self-reported nausea and its treatment varied by country. In more than 
half of the countries, treatment rates with conventional medicines were below 20%. 
In the majority of countries, antihistamines and metoclopramide were the most 
commonly used conventional medicines, and ginger the clearly most commonly used 
herbal medicine. Respondents who suffered from nausea also had a high burden of 
comorbidity. Overall, 74% of women had experienced nausea during pregnancy, of 
whom 18% had used conventional medicines and 8% had used herbal medicines. 
(Paper II). 
 
In the Norwegian study, we found that many women with moderate and severe 
symptoms did not receive any pharmacological treatment, 70% and 33%, 
respectively. Sick leave was prescribed without initiating medical treatment for 62% 
of the women. The women’s beliefs about medicines had an important impact on 
their use of medicines for NVP. Meclizine, closely followed by metoclopramide, was 
the most commonly used conventional medicine, while ginger and acupressure were 
the most commonly used CAM (Paper IV). 
 
The use of ginger during pregnancy was not associated with any increased risk of 
congenital malformations. No increased risk of stillbirth/perinatal death, preterm 
birth, low birth weight, or low Apgar score was detected for the women exposed to 
ginger during pregnancy compared to women who had not been exposed (Paper I).  
 
The GPs thought it was important to normalise NVP symptoms. However, the women 
felt their distress due to NVP was trivialised by the GPs. The women were sceptical 
about using medicines while pregnant, and they tried to avoid such use despite being 
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ill. The GPs appeared to be uncertain about medical treatment of NVP. They also 
expressed a lack of belief in the effect of medicines against NVP. Sick leave seemed 
to be an important part of the treatment regime applied by the GPs (Paper III).  
Moreover, from an academic perspective, this doctorial work has shown that use of e-
epidemiology and the internet enable efficient and unique data collections of high 
quality. This holds important promise for future studies.  
 5.2 Methodological considerations 
 5.2.1 Paper I The MoBa study: Safety of ginger use in pregnancy 
The MoBa and MBRN 
The MoBa study is exceptional in many ways. This large population-based study 
includes 95,000 pregnancies, 75,000 fathers and 114,500 children (258). The 
prospective nature of the data collection largely avoids recall bias and also diminishes 
the risk of differential misclassification of the exposure, with subsequent limited risk 
of biased measures of associations (259). Additionally, the vast diversity of 
information on health-related factors, sociodemographic and lifestyle factors enabled 
important potentially confounding factors to be controlling for in the multivariate 
models. 
The information in the population-based registry MBRN is also prospectively 
collected by healthcare personnel during pregnancy and at birth (242). MBRN 
provides medically confirmed records and is unlikely to suffer from selection bias 
given its population-based nature. 
Response rate, selection-bias and representativeness  
MoBa was based on self-selection. Of all the invited women, 40.6% consented to 
participate in MoBa, introducing a risk of selection bias. Indeed, it has been shown 
that, when compared to the total Norwegian birthing population, the women in MoBa 
differ with respect to several exposure and outcome variables (259). The youngest 
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women, smokers, those living alone, mothers with more than two previous births and 
with previous stillbirths are underrepresented in MoBa, while women who used folic 
acid and multivitamins are overrepresented. With respect to pregnancy outcomes, 
women with stillbirths or neonatal death were underrepresented. Nilsen et al. also 
examined for differences in association measures for eight well-known exposure-
outcome associations between the participants in MoBa and the general birthing 
population, but no statistically significant relative differences were found (259). The 
authors therefore conclude that, while these differences have implications for 
prevalence studies, the indications are that the exposure-outcome associations found 
in MoBa are valid. 
The selection bias, which could indicate that MoBa represents the more healthier 
segment of the population, could imply a higher prevalence of ginger use in MoBa, 
since it is found that non-smokers and/or women who use folic acid or multivitamins 
are more likely to use herbs during pregnancy (14, 260). However, the low 
prevalence of ginger use detected in MoBa indicates that this was not the case. As 
regards women experiencing NVP and women who were hospitalised due to 
prolonged NVP the prevalence found in both cases were similar to what is known 
from the literature (37). 
Information bias, reliability and validity of collected data 
Information about maternal sociodemographic, lifestyle characteristics and pregnancy 
originate from MoBa or the MBRN. Information retrieved from MoBa is dependent 
on the women’s accuracy of recall and reporting. In order to enhance recall and 
reporting of herbal products in MoBa, indication-oriented reporting of substances was 
applied. In addition, women were specifically asked in all three questionnaires to give 
the complete name(s) of all vitamins and dietary supplements they had used, 
including alternative/herbal remedies and dietary products. The information about 
ginger use was based on self-reporting which may introduce possible underreporting 
of use. Indeed, the prevalence of use was found to be of a much smaller magnitude 
compared to what is found in other studies (17, 123-125). Though these studies, many 
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of which were specifically designed to study the use of herbal products during 
pregnancy, may overestimate use due to selection bias, it is possible that the women 
in MoBa did not comprehend that the intake of herbs in all forms was to be reported. 
Ginger root can be used in fresh or dried form, in capsules, or prepared as a tincture 
or a tea. Fresh ginger root or ginger prepared as a tea may not be perceived as a 
‘medicine’. Furthermore, one third of the reported ginger use was independent of 
indication. A master’s thesis study conducted in Bergen, Norway in 2008–2009, 
found that the reported use of herbs during pregnancy increased from 35.2% in 
response to a general question about use of herbal products to 52.8% after asking 
about the use of ten specific herbs (261). 
Moreover, information about dosage and administration was not available in MoBa, 
which is indeed a limitation. However, estimating the correct dosage is a general 
problem when studying herbal medicines. Herbal products are seldom standardised. 
Herbal medicines may contain a large variety of constituents, and if the active 
component(s) is/are unknown, standardisation is not possible. Moreover, several 
environmental and genetic factors may affect the complex mixture of constituents 
(262). Climate, altitude and growing conditions, time of harvesting, which plant parts 
are used, storage conditions and processing treatments are all factors that can affect 
the quality and contents of the herbal product, and, consequently, the content may 
differ from product to product and even from batch to batch (262).  
All information retrieved from the MBRN is based on medically confirmed records 
and is prospectively collected during prenatal care and at birth. This information is 
therefore unlikely to suffer from recall or information bias. However, the possibility 
of random underreporting of minor malformations cannot be ruled out.  
Sample size and statistical considerations 
Power analyses revealed that the statistical power of our data was sufficient to rule 
out twofold or greater increases in the risk of outcomes that occurred more frequently 
than in 2% of the study population. For rarer outcomes, such as cardiac 
malformations, low Apgar score and stillbirth/perinatal death, the statistical power 
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was 60%, 72% and 50%, respectively. Consequently, even larger studies are needed 
to have adequate statistical power to rule out an increased risk of rare negative 
outcomes. 
 5.2.2 Papers II and IV The multinational and the Norwegian web-
based cross-sectional studies: Treatment of NVP  
The multinational and the Norwegian study of treatment of NVP shared many of the 
same characteristics in that they were both web-based surveys aiming to recruit 
pregnant women and new mothers. These two studies will therefore be discussed 
together in the following section. 
The multinational study of treatment of NVP was based on the Multinational 
Medication Use in Pregnancy Study. This study was unique in that the data were 
uniformly collected in the period between 1 October 2011 and 29 February 2012 from 
over 9,000 women from 18 countries. The Norwegian NVP study was the first of its 
kind to study the management of NVP according to severity in a Scandinavian 
country. Data from all over Norway were uniformly collected via the internet.  
Using an anonymous, web-based questionnaire was an approach that made it possible 
to reach a large sample of pregnant women and new mothers from several countries 
worldwide in the multinational study, and from all over Norway in the Norwegian 
study. The internet is increasingly used for online surveys and web-based research 
(263), and web-based recruitment methods have shown reasonable validity in 
epidemiological studies (264, 265). In various research fields, it has been found that 
the information reported in web-based questionnaires is of as good quality, equivalent 
to and as reliable as the information provided on paper (266-268). Furthermore, it 
was recently shown that information about chronic disorders among pregnant women 
was validly collected via web-based questionnaires with equal or better quality when 
compared to obstetric records (269). Electronic entry of data largely enables data 
entry errors to be avoided. 
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Response rate and representativeness 
Conventional response rates could not be calculated due to the web-based approach 
that was applied in the two studies. Response rates for web-based questionnaires have 
been studied, and the latest studies suggest that response rates in web-based studies 
are increasing, and are sometimes even higher than in paper-based studies (270). 
However, the response rates in web-based questionnaires seem to depend on the 
target population, the design and the context (271). Since pregnant women have been 
shown to be frequent users of the internet and the internet penetration rate is high 
among women of childbearing age (272-278), it is reasonable for studies targeting the 
pregnant population to adopt a web-based approach. The representativeness of the 
Multinational Medication Use in Pregnancy Study was assessed, as previously 
described in the Material and methods section. The participants were generally more 
highly educated than the general birthing population.  
Although there were slightly fewer smokers, and slightly more women using folic 
acid before the pregnancy, the study participants in the Norwegian study were 
reasonably comparable to the general Norwegian birthing population with respect to 
residential area, age, marital status, folic acid use and smoking status. However, also 
the participants in this study had a generally higher level of education than the 
women in the general population.  
The higher education of the respondents found in both studies may have had an 
impact on their choice of treatment. Moreover, with respect to the Multinational 
Medication Use in Pregnancy Study, the findings for the countries where the study 
sample only comprised a small part of the general birthing population should be 
interpreted with caution. 
Selection bias 
Banners with invitations to participate in the studies were posted on pregnancy and 
baby-related websites nationally and internationally. Hence, a risk of self-selection 
bias cannot be excluded. Efforts were made to reduce selection bias, such as 
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endeavouring to reach a wide proportion of the target population by posting the 
banners on two to three websites in each participating country in the multinational 
study. The national coordinators chose the most relevant websites, social networks 
and pregnancy forums in their respective countries. With respect to the Norwegian 
study, in addition to posting the banner on commonly visited websites, a link was also 
posted on a Facebook page specifically created for the study. Studies have shown that 
the vast majority of pregnant women go online for pregnancy-related information, 
most commonly visiting social networks and online discussion forums (272, 273). 
Moreover, the internet penetration rate is generally high among women of 
childbearing age (274-278). In Norway, 97% of women aged 16-44 use the internet 
on a daily basis (279). A selection bias with respect to the inclusion of slightly 
healthier and more educated women could still have occurred. However, this 
selection bias applies to most epidemiological research based on information 
collected from individuals. It is not a bias solely associated with studies using web-
based approaches (259). There is a possibility, though, that women suffering from 
nausea may have been more likely to seek information on the internet and, 
consequently, more likely to participate in the study. Moreover, women suffering 
from severe symptoms may be more motivated to participate in the study, which 
could explain the high prevalence of women with severe symptoms in the study 
population in the Norwegian study. Then again, the most severely affected women 
will be too sick to participate. 
The original data file from the Multinational Medication Use in Pregnancy Study 
included 9,459 women, 346 of whom were South American women who accessed the 
questionnaire via North American websites (15). The 346 women from South 
America were excluded from this current sub-study in an effort to reduce selection 
bias, as they were considered to be a special group of women. For the same reason, 
we also included level of education constructing the full multivariate models. 
However, the possibility that the respondents differ from the general birthing 




As the data in these studies are based on a self-completed questionnaire, the 
information provided is dependent on the women’s accuracy of reporting and recall. 
Hence, a recall bias cannot be excluded. Efforts were made to reduce the risk of recall 
bias, such as including women with a child of ≤ 1 year of age.  
With respect to the multinational study, the prevalence of nausea may have been 
underestimated due to the inclusion of women at an early stage of their pregnancy, 
since nausea often does not occur before gestational weeks 6–8. However, this only 
applies to the 182 women (2.0%) who were less than six weeks pregnant at the time 
of participation. The fact that we found a prevalence of nausea in line with the 
prevalence reported in the literature further supports our approach. The questions 
about use of medicines were indication-oriented, and a list of OTC medication 
categories together with brand name products was presented to the women in order to 
aid recall of these medicines. A similar approach was applied in the Norwegian study 
in which brand name products were presented together with drug name. 
In the Norwegian study, severity of symptoms was measured using PUQE (44). 
However, since maternal reporting of information was retrospective for women not 
being at the peak of their symptoms, a risk of overestimating the severity of 
symptoms was introduced. It has previously been demonstrated by Koren et al. that 
women have a tendency to overestimate the symptoms when reporting retrospectively 
(280). In an effort to reduce this risk, women whose youngest child was older than 
one year of age were not eligible to participate, but we cannot rule out this risk 
completely. However, another study that used the three PUQE questions to assess 
NVP retrospectively did not find evidence of differential recall when stratified by 
gestational age (281).  
Reliability and validity of data 
Nausea as a diagnosis was self-reported, depending on the women’s own perception 
of the complaint and accuracy of reporting, introducing a lack of validity. However, 
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as nausea is mainly a subjective complaint, self-reporting probably reflects the actual 
condition quite well. 
The EPDS is found to be an instrument with valid psychometric properties, also when 
administered on the internet (282). In this study, a cut-off score of ≥13 was applied, 
which is considered to have a high sensitivity (248). However, administration of 
EPDS at two time points is considered to be more valid than one to avoid detection of 
transient distress rather than depressive symptomatology (249). 
PUQE is a validated tool that has been shown to correlate with risk of hospitalisation 
due to severe NVP, increased healthcare costs because of NVP, reduced well-
being/quality of life, insufficient nutritional intake and inability to take iron 
supplements (256, 257). A translated Norwegian version of PUQE was recently 
validated (257).  
 5.2.3 Paper III The focus group study: Attitudes to and thoughts on 
treatment of NVP among pregnant women and general 
practitioners 
This study applied a qualitative approach to assess attitudes to and experiences of 
treatment of NVP among women and general practitioners. The strength of this study 
was that focus group discussions were carried out with representatives of both the 
healthcare providers and patients. Although this study is not generalisable beyond the 
participants in this setting, the data provide valuable insight into thoughts and 
attitudes among GPs and pregnant women that may be useful for GPs and other 
healthcare personnel who are in contact with this patient group. It is acknowledged 
that being a novice researcher in qualitative research has its limitations. Focus group 
discussions were chosen as a method, since it is known to be well-suited to gaining 
insight into the participants’ own experiences, thoughts and feelings (283). The group 
dynamic in a focus group may help people to explore and clarify their views, which 




Recruitment was slow in both groups of participants. This hindered a solely strategic 
sampling. The purpose of a strategic sampling is to identify specific groups of people 
who either possess characteristics or live in circumstances relevant to the social 
phenomenon in question, thereby enabling exploration from the widest possible range 
of views and/or experiences (234). With respect to the pregnant women, we had to 
apply snowball recruitment in order to enhance recruitment. This is obviously not 
ideal, as strategic sampling should be used to be able to widely explore the 
phenomenon in question. The Regional Committee for Ethics in Medical Research 
did not allow members of the research group to approach women for recruitment 
purposes. Instead, the recruitment process had to be conducted by healthcare 
personnel working at Kvinneklinikken, Haukeland University Hospital, who handed 
out an information pamphlet to women attending the clinic. Since the information 
pamphlet was sometimes handed out together with information about other studies, 
the recruitment process may have been impeded. However, despite the slow 
recruitment, our samples turned out to be quite diverse, with some exceptions. The 
women were generally highly educated, but age and parity varied among the 
participants. The low representation of women with lower levels of education may 
have affected our results. However, the women without a high education did not seem 
to feel constrained and they were well-accepted by the group, possibly because they 
had the illness in common. 
GPs were recruited by contacting educational groups in the county of Hordaland 
suggested by the chair of the Committee for specialisation in general practice. 
Despite the slow recruitment, the GP sample was also relatively diverse, varying in 
age and gender. However, several GPs had less than five years’ experience, which 
could partly explain the participating GPs’ uncertainty about the choice of treatment 
after dietary and life style advice was given. Furthermore, the groups of GPs 
belonged to the same educational group, which may result in opposing points of view 
being withheld in order to avoid conflicts. However, based on a good dynamic in the 
groups during the sessions, and a seemingly high tolerance of contradictory 
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statements, this did not seem to constrain the discussions and the participants seemed 
comfortable with the setting.  
Data collection, transcription and analysis 
Semi-structured focus group discussions were conducted to collect the data. The 
focus group discussions were moderated by pharmacists/master’s students in 
pharmacy. In the case of the focus group discussion with the pregnant women, a male 
master’s student in pharmacy acted as moderator, which may have had an impact on 
the discussion. However, this was discussed prior to and after the discussion, and our 
impression was that this did not seem to hinder disclosure of relevant information 
about the phenomenon in question. It is possible that it may even have been an 
advantage in that the women might have provided even more detailed descriptions to 
enable the moderator, as a male, to comprehend the situations/experiences being 
shared. Being a pharmacist interviewing GPs, was also considered to have a possible 
impact on the results obtained. In order not to be perceived as ‘intruders’ who were 
there to criticise how the GPs practise their profession, this was stressed prior to 
conducting the discussions. Our impression was that the discussions resembled 
informal, natural conversations. This is probably due to a perceived natural setting in 
that healthcare professionals from one field shared experiences with healthcare 
professionals from another field. Open-ended questions were prepared in the 
interview guides, although they were sometimes deviated from in order to facilitate 
more detailed follow-up of responses or ideas of special interest.  
The process of verbatim transcription of the audiotapes can also introduce errors 
(286). In an effort to reduce this risk, the audiotapes were transcribed by the 
moderator conducting the group discussion on the tape, with one exception. In the 
latter case, the moderator of the group quality-assured the transcript. Furthermore, the 
analyses of the transcripts were conducted by the researchers who had been present 
during the discussion, thereby enabling aspects of the interviews and group dynamics 
to be taken into account in the analytical process. There is nevertheless always the 
possibility of loss of information during translation, thereby affecting 
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reliability/dependability. The quotes presented in the paper were discussed with a 
native English speaker to try to reduce the risk of translational errors.  
Systematic text condensation is a strategy that was developed to provide the novice 
researcher with a tool that facilitates a process of intersubjectivity, reflexivity and 
feasibility while maintaining a responsible level of methodological quality (255). It 
was therefore considered an appropriate strategy in our context.   
Reliability and validity (dependability, credibility and transferability) 
Though repeatability is often used as a measure of reliability and reproducibility in 
medical research, it is not a direct criterion for reliability or dependability in 
qualitative research (283). Data collection, analysis, interpretation and presentation 
are affected by the researcher’s personality (283). Qualitative research acknowledges 
that there are several equally valid versions of knowledge (see section 1.9.2). 
Different researchers will interact with the group in different ways, follow different 
subthemes during the discussion, and find different nuances interesting when reading 
the same material etc. (283). While Mays and Pope recommend that the analysis 
should be repeated by more than one researcher to ensure validity/credibility (234), 
others argue that this is very difficult and perhaps not even appropriate due to the 
dynamic, socially constructed nature of reality (232). Armstrong et al. studied the 
extent to which six experienced qualitative researchers show consistency in their 
accounts after analysing a transcript and preparing an independent report (233). It 
was found that there was close agreement on the basic themes, but each analyst 
‘packaged’ the themes differently (233). In this study, a group approach was applied 
in order to ensure the credibility of the transcripts, as well as when performing the 
analysis in order to improve dependability (234). 
The potential for bias as a result of the preconceptions of the researcher has been 
identified as one possible problem with qualitative research. While Mays and Pope 
recommend that the theoretical framework and methods used in the research process 
should be accounted for (232, 234), others argue that the researchers’ preconceptions 
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should be articulated, especially since a theoretical framework  is not always applied 
(231, 232). The author’s preconceptions are outlined in the foreword to this thesis. 
The concept of validity, both in terms of credibility and transferability, should be 
carefully assessed in each step of the research process (230, 283). Mays and Pope 
describe different ways of improving validity in qualitative research (287). In this 
current study, the fact that the results from the focus group discussions with the two 
different groups of participants reflected each other to a great extent supports the 
validity and objectivity, or confirmability, of our findings. Respondent validation, 
‘member checking’, may be used to promote validity (287). This was applied to the 
women, but not to the GPs. However, a limitation associated with respondent 
validation is that the interpretation produced by the researcher is designed for a wide 
audience and will be different from the interpretation or perception of an individual 
informant due to their different roles in the research process (287). Lastly, the 
importance of providing a clear exposition of the methods applied, by giving a clear 
description of the data collection and analyses (287), is acknowledged and 
endeavours have been made to provide one.  
 5.3 Discussion of results 
 5.3.1 Treatment of NVP 
Though our findings indicate that nausea is prevalent, we found that the prevalence of 
treatment varied to a great extent between the countries. A low prevalence of NVP 
treatment (<20%) was found in several countries. Niebyl states that pharmacological 
treatment is necessary for approximately 10% of the women (42). However, no 
reference is provided with respect to what this estimate is based on. Gadsby et al. 
found that approximately 10% of women with NVP suffered from severe symptoms 
characterised by more than 300 hours of nausea and more than 40 episodes of 
vomiting in total (41, 48). As treatment of early symptoms is thought to reduce the 
risk of progression to more severe symptoms, as well as reducing the risk of 
hospitalisation (30, 32, 41), the proportion of women with NVP who are within the 
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target group for pharmacological treatment is probably higher than 10%. It is 
estimated that 35% of the women with NVP have symptoms that are of clinical 
significance (42), which is supported by the fact that 25% to 35% of the women with 
NVP had time lost from work due to NVP (48, 50). Furthermore, Vellacott et al. 
reported that daily vomiting occurred in 28% of the women with NVP (50).  
The Norwegian study showed that a large proportion of the women with moderate to 
severe symptoms did not receive any pharmacological treatment. This finding 
indicates that Norwegian women are treated late in the course of their NVP. The 
newly revised guidelines in the NEL suggest that women with moderate NVP should 
be offered treatment (33), which may facilitate improvements in this regards. 
In addition, we found a high degree of comorbidity among women with nausea. In 
particular, the association with symptoms of depression and with sick leave deserves 
attention, together with the finding of high prevalence of heartburn and reflux 
problems. Symptoms of depression and heartburn and reflux problems have also 
previously been associated with NVP (155), and treatment of heartburn and reflux 
problems has been found to alleviate NVP (208). Clinicians in contact with women 
with NVP should be aware of the high degree of comorbidity, and address these 
conditions if present. 
NVP should be regarded as a significant public health issue, as it has been shown to 
result in negative physical, psychosocial and financial consequences (39, 52, 53, 82, 
94, 96, 107, 108, 288). Optimal management is therefore of importance. It cannot be 
stressed enough that NVP is a condition that deserves and needs to be taken seriously 
by the medical community in order to reduce the suffering of these women to the 
greatest possible extent.  
Treatment of NVP in a multinational perspective 
In the multinational study, we found that approximately 7 out of 10 women in the 
total study population experienced nausea. This is in line with previous prevalence 
estimates in the literature (37). Though the prevalence of nausea was generally high 
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across all participating countries, some variations were found. To the best of our 
knowledge this is the first study to enable a reasonably direct comparison between 
several countries with respect to the prevalence of nausea during pregnancy, adding 
to the literature on the subject. However, we did not have data on the severity of 
symptoms. Fewest women reported nausea in Russia, Croatia and Serbia, while most 
women reported nausea in Iceland, Sweden and the USA. The comprehensive review 
conducted by Einarson et al. in 2013 also found a wide range of prevalence estimates 
reported from various countries (37). However, as the studies differed in the 
methodologies applied, such as varying definitions of NVP, inclusion criteria and 
source population, direct comparison was problematic. Einarson et al. state that little 
is known about the prevalence of NVP in the Eastern European countries and less 
developed countries in general. The observed dissimilarities between countries may 
be explained by cultural differences that are reflected in differences in self-perceived 
illness, differences between various ethnic groups’ genetic predisposition, or 
differences in healthcare systems. Our study adds to the literature by providing 
prevalence rates for the participating countries in Eastern Europe, but little is known 
about the countries in South America, Africa and large parts of Asia (37). 
Overall, of the respondents who had experienced nausea, 27% had used some type of 
treatment against nausea, and 18% had used conventional medicines to treat this 
complaint. Previously reported prevalence estimates for use of conventional 
medicines for nausea are shown in table 3, section 1.8 (52-54, 94, 166, 197, 218-221, 
224). However, direct comparison with previously reported prevalence estimates is 
problematic due to large variations in the methodologies applied and differences 
between the countries in which the research was conducted. Furthermore, as we do 
not have data on the severity of nausea, we cannot determine whether the respondents 
suffered from mild symptoms that were sufficiently managed by non-
pharmacological treatments, such as changes in diet and lifestyle that may explain our 
result.  
Nevertheless, our observed country-specific estimates of use of treatment showed 
large variations. Women with nausea residing in Slovenia, Croatia, Finland and 
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Poland showed the lowest use of medicines for nausea, as opposed to women from 
Canada, France, Sweden and Switzerland, who showed the highest use. Several of 
our findings can be explained by cultural differences and differences in access to 
prenatal care and treatments, as well as their relative costs. Differences between 
various national guidelines or lack thereof may also be a reason. Furthermore, 
variations in the women’s self-perception of severity of symptoms and the general 
practitioners’ and women’s risk perception as regards the use of medicines during 
pregnancy are reflected in both groups’ attitude to treatment, and this may also 
explain our findings (289-292). According to the current literature, the extent of use 
of medicines against nausea has been highest in Canada, Australia and France (see 
Table 3 in section 1.8), which correlates well with our results.  
No data were found about the treatment of nausea in countries in Eastern Europe. 
However, Serbia is known to have a low extent of use of medicines in general during 
pregnancy (15, 293). Interestingly, compared to the prevalence of HG of 1.1% found 
in a recent meta-analysis (37), a relatively high prevalence of 3% of HG is reported in 
Russia (294), and a high prevalence of 10% (17.5% of 58% with nausea) of severe 
NVP is reported in Serbia (295). Since treatment of early symptoms is believed to 
reduce the risk of progression to more severe symptoms as well as hospitalisation (30, 
32), it may be hypothesised that the high prevalence of HG/severe symptoms could 
be explained by suboptimal treatment, based on the low estimates of use of medicines 
detected in these countries. In most Eastern European countries, antacids were the 
most commonly used conventional medicines against nausea, which deviates from 
the first line treatment recommendations for NVP in major guidelines (27, 28, 30-32). 
This could indicate that comorbidities associated with nausea are treated more than 
the nausea itself. 
In the vast majority of countries, antihistamines and metoclopramide were the most 
commonly used conventional medicines against nausea. In the USA, ondansetron was 
most commonly used. The differences found between countries with respect to the 
types of treatments most commonly used are in line with findings from a study of HG 
treatments (226). This study found that antihistamines were most commonly used in 
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Canada and that serotonin inhibitors were most commonly used in the USA, whereas 
Australia had the highest reported use of promotility agents such as metoclopramide 
(226). The same study also noted that women from Canada used less intravenous 
hydration and parenteral nutrition than women from the USA, commenting that this 
could be explained by more efficient treatment by physicians made possible by the 
availability of Diclectin® on the Canadian market (226). This is in line with another 
study finding, namely that Canadian women had less lost time from paid work, were 
hospitalized less often due to NVP and had suffered less weight loss when compared 
to American women (224).  
The high use of antihistamines is in accordance with recommendations in major 
guidelines (27, 28, 30-32). Dopamine antagonists such as metoclopramide are 
commonly referred to as second line treatment options, after doxylamine/pyridoxine 
or other antihistamines (27, 30-32). While no increased risk of malformations is 
associated with the use of either antihistamines or metoclopramide (164, 175, 176), 
both the foetal and maternal safety of ondansetron has recently been questioned 
(193). Concerns about cardiac malformations have been raised. Though two Danish 
studies reporting opposing results regarding the risk of cardiac malformations made it 
difficult to conclude (194, 195), the concerns were recently strengthened when a third 
study also detected a modestly increased risk of cardiovascular and cardiac septum 
defects (196). As regards maternal safety, cardiovascular safety concerns were raised 
by the FDA in 2011, suggesting that ondansetron could cause QT prolongation, 
leading to Torsade de Pointes (200). Lately, maternal safety concerns have also been 
raised with respect to metoclopramide. EMA’s recommendation of restricting the use 
of metoclopramide to maximum five days will probably limit metoclopramide’s role 
in the treatment of this pregnancy complaint (189). The consequence is that pregnant 
women are left with fewer available agents for the treatment of NVP. The safety 
documentation pertaining to the use of the other dopamine antagonists, such as 
chlorpromazine and prochlorperazine, during pregnancy is less extensive, although 
the available evidence generally points to both agents being safe to use during 
pregnancy (9, 182-184, 187). Benefit-risk assessments may in some cases still favour 
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treatment by metoclopramide, and pregnant women prescribed metoclopramide for 
NVP should be closely followed up with respect to neurologic side effects. 
Treatment with herbal medicine among women with nausea was highest in Australia, 
Iceland and Slovenia; and lowest in Sweden, Croatia and Finland. The high use in 
Australia and the low use in Sweden are in line with previous findings (123, 296, 
297). Pregnant Australian women have also previously been found to use herbal 
drugs, and CAM in general, to a high extent (123, 296). At the opposite end of the 
scale, a previous study based on the Swedish Medical Birth Register reported a 
prevalence rate as low as 0.9% for the use of herbal drugs among pregnant women of 
whom surprisingly few, only 0.6% of the users, had used ginger (297). The low use 
of ginger was mainly explained by high use of OTC antihistamines against NVP 
(297), an explanation that could probably be extrapolated to apply to our result as 
well. In 2009, the Finnish food safety agency, Evira, issued a warning based on the 
precautionary principle about the use of ginger during pregnancy due to alleged 
harmful constituents posing a risk to the foetus (298). That may explain the low use 
in this particular country. 
Ginger was the most commonly ingested herbal agent for NVP. This was not 
surprising since ginger is included in major guidelines for the treatment of NVP (27, 
28, 30-32).  
Treatment of NVP in Norway 
Compared to the multinational study, we found a relatively high prevalence of 38.9% 
for the use of medicines for NVP in the Norwegian study. This is probably due to the 
fact that the women who participated in the latter study generally suffered from 
moderate or severe symptoms, 61.7% and 29.5%, respectively. Not surprisingly, 
medicines were increasingly used with increasing severity of NVP. Among women 
with mild NVP, only 8.2% had used any antiemetics. Note, however, that negative 
impact on the women’s quality of life and a clinically important prevalence of 
psychosocial problems have also been found among women with mild NVP (53, 95). 
Although the effects is more magnified in moderate or severe NVP, significant 
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adverse effects on eating and nutrition, domestic and occupational and social life 
were also detected among women with mild NVP in an American study (95). In a 
Canadian study, one in five women with mild NVP reported feelings of depression 
always or most of the time, and 43% reported adverse effects on their partner’s daily 
life (53). We also found that a large proportion of the women with moderate and 
severe NVP, 70.2% and 32.9%, respectively, did not use any antiemetics, which 
warrants attention. Optimal management is particularly important in cases of severe 
NVP/HG, since it was found that use of antiemetics was more frequent among 
women who only considered and women who never considered termination 
compared to women who did terminate their pregnancy due to NVP/HG (97). 
Moreover, almost two-thirds of the women had been on sick leave due to NVP, many 
of whom did not receive antiemetics prior to being put on sick leave or at any time 
during their pregnancy. These findings could either be due to healthcare personnel 
being reluctant to prescribe any antiemetics or to the women not being willing to take 
medicines. 
Meclizine was the most commonly used medicine for NVP, and metoclopramide 
came second, which is in accordance with the Norwegian guidelines (33, 34). 
However, approximately half of the women using only one medicine had not used an 
antihistamine, indicating that deviations from the treatment guidelines occur. The 
choice of treatment is based on an individual risk-benefit assessment together with 
clinical judgement, which may explain this finding. The fact that metoclopramide had 
almost as many users as meclizine was surprising, especially in light of the recent 
warning issued by the EMA. Sub-analyses including women who were pregnant at 
the time of participation revealed that a large proportion of the women using 
metoclopramide used it for more than one week. These women must have used 
metoclopramide after the EMA warning was issued, indicating that the EMA warning 
is not generally known or accepted among GPs. The high degree of use of 
metoclopramide can probably be explained the fact that the majority of the 
respondents were suffering from moderate and severe symptoms, which may not have 
been sufficiently managed by antihistamines. Ondansetron was the third most 
commonly used medicine, used by 7% of the women. While treatment with either 
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meclizine or metoclopramide was initiated by a general practitioner, ondansetron was 
most often initiated by a gynaecologist or a hospital physician. It is listed as a third 
line treatment option recommended for patients with more severe symptoms in 
several guidelines (27, 31, 34). This is in line with our finding that women with 
severe NVP or who were hospitalised were significantly more likely to have used 
ondansetron.  
Nearly all the women reported having tried dietary and lifestyle changes in an effort 
to reduce the NVP symptoms. The use of CAM was high, which is in line with 
findings from several prior studies (14, 17, 124, 223, 299). As in the multinational 
study, ginger was the most commonly used herbal medicine. Acupressure was also a 
commonly used CAM. CAM use as a whole was greater than use of conventional 
medicines, but herbal medicines alone were used to an almost equal extent as 
conventional medicines. Although herbal medicines were used by only half as many 
women as conventional medicines overall in the multinational study, among the 
Norwegian women in that study, the use of herbals was almost equal to the use of 
conventional medicines, which largely concurs with our results in this study. The 
extensive use of CAM and changes in dietary and lifestyle are in line with guidelines 
recommending first trying conservative approaches (such as dietary and lifestyle 
changes, ginger, acupressure and/or acupuncture) before using any medicines.  
 5.3.2 Factors associated with the use of treatment against nausea 
In the multinational study, it was found that respondents who had lower education, 
worked as healthcare professionals or women with a multiple pregnancy were more 
likely to use medicines against nausea. The Norwegian study also identified 
education and employment status as factors predicting use. However, in this study it 
was found that fewer women with a master’s degree, or who were unemployed used 
medicines for NVP compared to women who had a bachelor’s degree or were 
currently employed. Though our findings in the two studies were not identical, they 
are not necessarily contradictory. Direct comparison is problematic due to differences 
in variable classification. 
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Education and employment status are both factors that have also previously have 
been associated with the use of medicines for NVP. A previous study from Sweden 
found that women with lower levels of education used medicines to a greater extent 
than women with higher education (166), and Markl et al. from Germany found that 
unemployed women and women on welfare had a higher chance of getting a 
prescription for medicines for NVP than ‘blue and white collar workers’ (219). The 
observed discrepancies may be explained by cultural differences between the study 
populations. 
The association between the use of medicines and multiple pregnancy could indicate 
that the use of medicines may act as a marker of severe forms of nausea, as it has 
previously been found that multiple pregnancy increases the risk of nausea (300). The 
severity of nausea was indeed strongly associated with the use of treatment in the 
Norwegian study, which is in line with previous studies (53, 79). Since no firm 
conclusion can be drawn with respect to maternal characteristics predicting use of 
treatment, exploring women’s beliefs and the severity and impact of symptoms is 
probably a better approach. 
 5.3.3 Safety of use of ginger during pregnancy 
Ginger was frequently used for NVP in both the multinational and the Norwegian 
study. However, little is known about the safety of ginger, other than that no reports 
of increased risk of malformations or any other impact on pregnancy outcomes have 
been filed, neither from a rather small prospective study including 187 pregnant 
women who used ginger, nor any of the randomised controlled clinical trials studying 
the effect of ginger against NVP (143, 154). Furthermore, no case reports about any 
negative impact of ginger use on pregnancy outcomes have been detected.  
To our knowledge, this study is the largest study yet to investigate the safety of 
ginger use in pregnancy, and the results are reassuring: using ginger during 
pregnancy does not seem to increase the risk of malformations or negative pregnancy 
outcomes such as still birth/perinatal death, preterm birth, low birth weight and low 
Apgar score. A small increased risk of vaginal bleeding was observed among ginger 
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users. However, when the analyses were restricted to more severe bleeding, no 
association was found. Moreover, sub-analyses stratified by timing of use did not 
detect any association between the bleeding outcomes and use of ginger either.  
The results of this study add valuable knowledge that strengthens our confidence in 
the findings of the safety evaluation study by Portnoi et al. and the clinical trials 
(154). Since ginger was commonly used both in Norway and internationally, these 
findings have valuable clinical implications as they provide healthcare professionals 
with more evidence when discussing ginger use with pregnant patients. However, 
women struggling with severe symptoms and/or heartburn and reflux problems 
should probably be recommended to avoid ginger, as ginger may exacerbate these 
symptoms (156). 
In Norway, herbal products are available as herbal medicinal products classified 
according to well-established or traditional use as described in the EU regulations 
(301), and as dietary supplements (302). For a product to be registered as a herbal 
medicinal product, specific requirements apply with respect to the demonstration of 
traditional use within the EU, the safety and quality of the product, including 
complying with good manufacturing practice (GMP) and European Pharmacopeia 
standards (262), as well as compulsory pharmacovigilance. In contrast, dietary 
supplements are only notified to the Norwegian Food Safety Authority, and 
pharmacovigilance of these products is not compulsory. To date, only 14 herbal 
medicinal products exist on the Norwegian market (303), none of which contain 
ginger, which means that most herbal medicines are unregulated products classified 
as dietary supplements. Consequently, little is known about their quality, safety and 
effectiveness of use. This should be taken into consideration when herbal products 
are considered for use by pregnant women. 
 5.3.4 Attitudes to and thoughts about treatment of NVP  
The qualitative study conducted with GPs and pregnant women provided a deeper 
insight into both groups’ attitudes to and thoughts on treatment of NVP that adds to 
the findings from the multinational and the Norwegian study of treatment of NVP. 
 99
Both studies indicate the presence of suboptimal treatment of NVP, which is 
especially important among women with moderate and severe symptoms.  
The most important finding in the focus groups study is that the pregnant women and 
the GPs seem to talk at cross purposes. While the women wanted their problems to be 
acknowledged, the GPs emphasised normalising the symptoms. This was done with 
good intentions in an effort to reduce the women’s possible anxiety about nausea 
harming their foetus. Although it is probably worth mentioning, too much emphasis 
on normalisation or trivialisation of symptoms can make the women feel that they are 
not being taken seriously. A low level of belief in the patients may result in delayed 
intervention, and consequently affect the time required for recovery (215). This 
illustrates the importance of a good patient-GP relationship. However, a recent 
master’s project that collected data on various aspects of the experience of HG among 
Norwegian women found that half of the women had not initially been taken 
seriously by their GP, and 21% of the women changed their GP due to inadequate 
treatment (304). With the exception of hospital physicians, the women had the 
impression that there was a lack of knowledge about HG among healthcare personnel. 
Both of these findings are in line with our findings, and may contribute to a delay in 
the initiation of treatment in primary care. Healthcare personnel should also inform 
women that symptoms may worsen to become as severe as merits hospitalisation. 
Hence, they should advice women on when to seek medical care, and explain the 
benefit and importance of seeking help to reduce symptom severity.  
Furthermore, the women missed being properly evaluated in an effort to address 
symptom severity and impact. This was more or less confirmed by the GPs, who 
admitted that, due to a busy schedule, at the first antenatal consultation, and due to 
the fact that the presence of nausea was expected, nausea was simply confirmed 
without being carefully assessed. The fact that national and international guidelines 
stress the importance of reassuring women that nausea is a normal part of pregnancy 
may explain these findings (28, 35, 36). The lack of proper evaluation has been 
documented in previous studies as well. An American study from 2013 reported that 
two thirds of the women with NVP missed being evaluated by professionals about the 
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impact of their symptoms on daily life functioning (95). However, obtaining 
information about severity and impact of symptoms may facilitate healthcare 
personnel in providing individualised treatment strategies.  
Sick leave was a topic that was spontaneously brought up by the GPs when treatment 
of NVP was addressed. The impression was that sick leave was a measure commonly 
used by the GPs as part of the treatment of NVP, often without concomitant 
prescribing of medicines, which is in line with previous findings in the Norwegian 
study of treatment of NVP. Sick leave was also associated with nausea in the 
multinational study. A prior study from Norway found that NVP was one of the most 
common reasons for sick leave during pregnancy, being responsible for 33% of all 
sick leave during pregnancy (3). Most of the women in the focus group had been on 
sick leave due to NVP. However, the women emphasised that, if it was possible to 
keep a part-time position, this was welcomed as it enabled some social contact. 
Feelings of isolation have previously been reported by women suffering from NVP 
(96). Though sick leave enables women to rest when necessary during daytime, it 
does not provide relief from the symptoms when caring for other children or doing 
household chores and should consequently not be viewed as an adequate substitute 
for antiemetics. Furthermore, prescribing sick leave without the concomitant 
prescription of antiemetics may send a message to the women that there is nothing 
more to be done, leaving the women isolated in their own misery. Sick leave could 
also have been perceived as an ‘easy way out’ of the treatment dilemma for both 
parties, as it is a ‘treatment’ option that does not involve exposing the foetus to drugs, 
which both groups, the women and the GPs, view as potential teratogenic substances.  
The GPs also seemed confident about giving dietary and lifestyle advice to the 
women. The advice referred to by the GPs included dry biscuits, eating before getting 
up in the morning and ensuring an adequate intake of fluid. However, detailed dietary 
and lifestyle changes that help to maintain adequate hydration and nutritional status 
are available (121), which could also be beneficial for Norwegian women to know 
about.  
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Both groups showed reluctance about treating NVP with medicines. References to the 
thalidomide tragedy were made by both groups. The thalidomide tragedy taught us an 
important lesson that medicines may impact foetal development. The take-home 
message from this tragedy should rather be a lesson about how to use medicines, not 
to strive for complete avoidance. Even though the women in the focus group 
discussions clearly wanted their problems to be acknowledged, they sent rather mixed 
messages about treatment. They criticised the GPs for not offering any prescription of 
medicines, but they clearly tried to avoid using medicines.  
This is in line with the findings revealed in the Norwegian cross-sectional study that 
women’s beliefs had an important impact on their use of medicines for NVP. Severity 
of symptoms was also associated with the women’s attitudes. Our findings may 
indicate that the women become more open to treatment the larger the burden of the 
illness, which is reasonable. Still, even women with severe symptoms generally 
showed a restrictive attitude towards medicines. These findings show that there is a 
need for comprehensive and reassuring information about treatment options to reduce 
women’s anxiety and insecurity, which influence their willingness to adhere to 
treatment (305). It has been shown that counselling and proper risk communication 
can reduce women’s negative beliefs about medicines and increase adherence during 
pregnancy (306, 307). Taking time to explore women’s perceptions and knowledge 
could be essential to ensure adequate NVP treatment and should be incorporated in 
clinical guidelines. 
However, the GPs that participated in the focus group discussions seemed to be 
uncertain about medical treatment of NVP, and they wanted a medicine with NVP as 
approved indication, especially in light of the warning about metoclopramide issued 
by the EMA. They also expressed a lack of belief in the effect of commonly used 
medicines against NVP. So, before GPs can counsel the women and provide proper 
risk communication about treatment of NVP, they must first have accurate knowledge 
about and confidence in safe treatment options for this complaint.  
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 5.4 Clinical implications and future perspectives 
Several of the findings in this thesis are of clinical importance in the fields of 
obstetrics, primary care and pharmacy. The prevalence rate of treatment of NVP 
showed intercountry variations, and the type of treatment of NVP most commonly 
used also varied across countries. As discussed above, there may be several 
explanations for the detected variations, including differences between national 
guidelines or lack thereof. Efforts should be made to educate healthcare personnel 
involved in pregnancy care about the available evidence-based information 
concerning treatments for NVP. Relevant sources of evidence-based information 
should be easily accessible and made well-known to the medical community. 
Guidelines should be updated in accordance with the findings from rigorous and 
repeated studies. They should be clearly written, so that they are easily 
comprehensible, and they should offer conclusive guidance to avoid leaving the 
clinicians in a dilemma about whether to medicate or not, which may give rise to 
differences in the type of care offered to the patients. An important step forward in 
Norway is the recently adopted revision of the NVP/HG guidelines in the NEL, in 
which PUQE is now included and impaired quality of life among women with 
NVP/HG is more directly addressed (33). 
The prevalence of nausea also varied to some extent between countries. This is the 
first study to enable a reasonably direct comparison to be made between countries 
with respect to the prevalence of nausea, adding to the literature on the subject. 
However, we did not have data on the severity of symptoms. Our study adds to the 
literature by providing prevalence rates for the participating countries in Eastern 
Europe, but little is still known about the countries in South America, Africa and 
large parts of Asia (37). Future studies should aim to close this knowledge gap. 
The prevalence rate for use of medicines in Norway was low compared to many other 
countries, and, according to our findings from the study conducted among Norwegian 
women, many women with moderate and severe NVP did not use any medicines. 
Furthermore, the qualitative study indicated that both GPs and pregnant women were 
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wary of prescribing or taking antiemetics for NVP. GPs seemed to be little aware of 
the negative consequences of NVP, and a proper clinical examination of the severity 
of the symptoms was seldom performed due to lack of time. These findings deserve 
attention. As elaborated above, women with NVP have an impaired quality of life and 
a high burden of comorbidity. The consequences of not being properly treated can be 
devastating (38, 39, 41, 84, 96, 97, 104, 106) and need to be acknowledged by 
healthcare providers involved in pregnancy care, so that women presenting with NVP 
are taken seriously. The newly revised NEL guidelines recommend that women who 
are classified as having moderate NVP according to PUQE should be offered 
pharmacological treatment (33). However, it is important to also assess the impact of 
symptoms on daily life functioning, mental health and occupational life, and to 
evaluate the woman’s social support system.  Moreover, clinicians should pay 
attention to the high degree of comorbidity among women with NVP and examine 
these women for symptoms of depression, and heartburn and reflux problems, which 
should be addressed if present. Future studies should investigate whether treatment of 
early symptoms reduces sick leave and progression to severe symptoms, as well as 
investigating whether combination therapy should be preferred over monotherapy, 
and whether daily and consistent dosing is superior to an ‘as needed’ regime. The 
treatment offered in primary care should also be investigated in more detail, and the 
factors that influence the decisional process with respect to medical treatment for 
NVP should be studied. 
Advice on dietary and lifestyle changes seems to be a welcome option among 
women. The women would probably benefit from more detailed advice about dietary 
and lifestyle changes that contribute to maintaining adequate hydration and 
nutritional status (121). This knowledge should be obtained by Norwegian healthcare 
providers and disseminated to the pregnant population.  
Since ginger was shown to be widely used for NVP, our findings about the safety of 
using ginger during pregnancy were reassuring and may help healthcare personnel 
when discussing use of ginger during pregnancy. However, they need to be replicated 
by future studies in order to draw a firm conclusion.  
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Our findings about women’s beliefs and attitudes are also of interest. Awareness of 
the association between women’s beliefs and use could assist clinicians when 
discussing treatment with pregnant women. Our findings indicate that women 
probably need comprehensive and reassuring information before considering using 
any medicines. But before GPs can take this position, they must obtain updated 
evidence-based knowledge and have confidence in the treatments available for NVP. 
The GPs in the focus group discussion wanted a medicine with NVP as approved 
indication, which should be noted by the health authorities in Norway.  
This is also a context in which pharmacists can prove valuable. Pharmacists are easily 
accessible healthcare personnel for pregnant women who need advice about how to 
handle symptoms of NVP. Pharmacists have a unique opportunity to counsel women 
early in their pregnancy about recommended dietary and lifestyle changes to relieve 
symptoms of NVP and facilitate adequate hydration and nutritional status. Though no 
medicine is available OTC in Norway for NVP, pharmacists can play an important 
role in educating women that there are medicines available on prescription that can 
help, and in providing proper risk communication and encouraging optimal 
management of NVP. It is therefore important that pharmacists are trained in how to 
counsel these women, so that they can give specific advice on how to best manage 
NVP in practice. Pharmacists could also play an important role in detecting women 
who need close follow-up and adequate medical treatment, and refer them to their GP 
when appropriate.  
So far, very little research has been conducted on maternal safety of use of 
metoclopramide for NVP. The few available randomised control trials and other 
studies primarily evaluate the effectiveness of metoclopramide for NVP (174, 177-
179). Larger studies specifically addressing maternal safety are warranted.  
Because of the EMA warning about metoclopramide (189), other dopamine-
antagonists may be increasingly used. More evidence is needed of the safety, both 
maternal and foetal, of the use of chlorpromazine and prochlorperazine. There is also 
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conflicting evidence about the safety of ondansetron intake during pregnancy, and 
further studies are needed before a firm conclusion can be drawn. 
In conclusion, our findings indicate that improvements should be made with respect 
to the health care provided for pregnant women suffering from NVP. We appear to be 
still struggling with the aftermath of the thalidomide tragedy that taught us an 
important lesson about how medicines can impact foetal development. Both GPs and 
women have the thalidomide story and/or the fear of drug teratogenicity at the back 
of their mind, which probably affects their decision-making as regards treatment. 
This is a paradox, however, since safe treatment options exist for NVP today. 
Acknowledging that NVP is a significant public health issue, optimal management of 
NVP will provide women, the healthcare system and the society as a whole, with 
great relief.  
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Advice to healthcare professionals  
- As stated by participants in the Norwegian cross-sectional study of 
treatment of NVP.  
‘Please take us seriously! Listen to us! We are not all just hysterical, hormonal 
mothers-to-be.’ A 22-year-old new mother from Western Norway. 
‘Take NVP seriously. Despite knowing that it will pass, for many women, it means 
several months of incapacitation. It is important to be knowledgeable about treatment 
and medicines. Don’t trivialise the condition. Don’t say things like: you should be 
glad that you are able to have children.’ A 26-year-old new mother from South East 
Norway.  
‘Take pregnant woman seriously. It is a high threshold to cross to come and ask for 
help. It is therefore very important that we are met with understanding.’ A 40-year-
old woman from Western Norway in pregnancy week 31. 
‘Listen to each and every one of us, and tell us that something can be done. At the 
same time, remind us that these problems will only last for a short period of our 
lives.’ A 23-year-old woman from Western Norway in pregnancy week 34. 
‘Take us seriously. Treat us earlier when necessary. Give concrete advice! Don’t just 
say: this is normal.’ A 31-year-old woman from South East Norway in pregnancy 
week 18. 
‘It is important to be supportive, and show that you understand that NVP can be 
tough, even in the absence of vomiting. Offer to help, explain about the risks and 
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Abstract
Background: The factors related to the treatment of nausea during pregnancy have not yet been investigated in
several countries simultaneously. The present study aimed to describe differences in self-reported nausea during
pregnancy and the patterns of use for both conventional and herbal medicines across countries. The factors related
to nausea and its treatment and the relationships between different self-reported co-morbidities and nausea were
also investigated.
Methods: This cross-sectional study used data collected by a web-based questionnaire distributed between October
2011 and February 2012 in several countries within five regions: Western, Northern, and Eastern Europe, North America,
and Australia. Women who were pregnant or had a child less than one year old were eligible to participate.
Results: A total of 9113 women were included in the study, whereof 6701 (73.5 %) had experienced nausea during
pregnancy. Among respondents with nausea, conventional medicines were used by 1201 (17.9 %) women and herbal
medicines by 556 (8.3 %) women. The extent of self-reported nausea and its treatment varied by country. Education,
working status, and folic acid use were significantly associated with the use of conventional medicines against nausea.
Respondents who had nausea also had a high burden of co-morbidity.
Conclusion: The prevalence of nausea was high across all participating countries but its treatment varied, possibly due
to cultural differences and differences in attitudes towards medicines. A high degree of co-morbidity was found among
respondents with nausea.
Keywords: Nausea, Pregnancy, Pharmacotherapy, Herbal medicine, Multinational, Internet
Background
Nausea and vomiting during pregnancy (NVP) is one of
the most common pregnancy-related complaints, affecting
millions of pregnant women worldwide each year. Ap-
proximately 7 out of 10 women experience nausea during
pregnancy [1] and 50 % experience both nausea and
vomiting [2–4]. For most patients, symptoms appear
around the sixth week of pregnancy and gradually decline
during the second trimester, peaking at 8–13 weeks [2, 3].
However, 10 % of women will still experience symptoms
after 20–22 weeks of pregnancy [3, 4]. The most severe
form of NVP, hyperemesis gravidarum, is characterised by
severe and persistent nausea and vomiting leading to
weight loss, ketonuria, nutritional deficiencies, dehydra-
tion and electrolyte imbalance, often so severe as merits
hospitalisation, and affects about 1.1% of the pregnant
women [1].
NVP has been shown to greatly impact a woman’s life,
negatively affecting daily activities, relationship with
partner, parenting, occupation and social functioning
[5–7]. Feelings of isolation, fatigue, depression, and help-
lessness due to nausea have also been described [7–9].
Nausea has been reported to be responsible for 33 % of all
sick leave during pregnancy [10]. In the USA and Canada,
NVP is a significant economic burden to women and
society [11, 12].
Because NVP is often most intense during the first
trimester when organogenesis occurs, teratogenic effects
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are a concern in treatment. This may lead to caution in
prescribing and taking conventional medicines to treat
this condition, despite the proven safety of use during
pregnancy of many medicines. Pregnant women often
overestimate the teratogenic risk associated with the use
of medicines in general [13]. Consequently, many women
may turn to complementary and alternative medicine
(CAM) to alleviate their symptoms or choose to not treat
their symptoms due to the fear that taking anything dur-
ing pregnancy may harm the baby. Despite the high preva-
lence of NVP, little is known about differences in NVP
treatments, i.e. conventional and herbal medicines, across
countries. An informal survey in various European
countries in 1998 found wide variations in the types of
treatment used against mild and moderate nausea and
vomiting, whereas hyperemesis gravidarum was treated in
a similar fashion in the vast majority of countries [14].
No study has investigated the factors related to NVP
treatment in several countries simultaneously. Studies
are available from various countries, but data collection
methods vary [5, 7, 15–20], making direct comparisons
impossible. In addition different therapies have been in-
cluded in the definition of CAM [15, 16, 18, 19].
New possibilities for uniform data collection in several
countries are emerging that are advantageous for the field
of e-epidemiology [21, 22]. Large potential gains in well-
being for the mother and society as a whole can be
achieved with better knowledge on how nausea in preg-
nancy is being treated. This study is the first to investigate
the factors related to the treatment of nausea during
pregnancy at a multinational level.
The present study aimed to describe differences in
self-reported nausea during pregnancy, as well as the
patterns of use of both conventional and herbal medi-
cine across countries in Western, Northern, and Eastern
Europe, North America, and Australia. The study also
aimed to investigate the factors related to nausea and its
treatment, as well as the relationships between different
self-reported co-morbidities and nausea.
Methods
This cross-sectional study was based on data from a web-
based questionnaire covering nausea, medicines against
nausea, herbal medicines against nausea, sociodemographic
factors, maternal health, and lifestyle during pregnancy
[23]. The online questionnaire was distributed simultan-
eously in 18 countries: Austria, Australia, Croatia, Canada,
France, Finland, Iceland, Italy, Norway, Poland, Russia,
Serbia, Slovenia, Sweden, Switzerland, the Netherlands,
United Kingdom, and USA. The original data file consisted
of 9459 women, including 346 South American women
who accessed the questionnaire via North American web-
sites [23]. For this sub-study, the 346 women from South
America were excluded in effort to reduce selection bias as
this was considered a special group of women, resulting in
a final study population of 9113 women.
Women who were pregnant or had a child who was less
than one year old were eligible to participate in the study.
An advert containing a link to the online self-completed
questionnaire was posted on commonly visited pregnancy
and baby related websites in the participating countries.
National coordinators selected the most relevant na-
tional websites, social networks, and pregnancy forums
[23]. The questionnaire was available for 2 months in
each participating country between 1st of October 2011
and 29th of February 2012.
The questionnaire was originally developed in Norwe-
gian and English before being translated into the relevant
languages, and is available online as an appendix to the
paper by Lupattelli et al. [23]. A pilot study was performed
during September 2011 in Norway, Finland, Italy, and
Sweden (n = 47) but resulted in no major changes to the
questionnaire. All national coordinators assured the qual-
ity of their version of the questionnaire.
The representativeness of the study population was
assessed by comparing the sociodemographic and lifestyle
characteristics (i.e., age, marital status, education, and
smoking) of the study population to the general birthing
population in the corresponding country. The similarities
were satisfactory with the exception that the study partici-
pants were generally more educated than the general
birthing population, as described in detail elsewhere [23].
Measures of nausea, health disorders, and conventional
and herbal medicines use during pregnancy
The respondents were presented with a list of questions
related to different health disorders/short-term illnesses
during pregnancy, including nausea, and asked if they had
any of these illnesses. In case of an affirmative response,
the respondents were asked about medicine use related to
each individual illness. The medicines used were reported
in free-text entry fields. The timing of use for both con-
ventional and herbal medicines could also be reported and
were defined by the three possible exposure windows in-
cluded in the questionnaire: weeks 1–12 (first trimester);
weeks 13–24 (second trimester), and week 25 to delivery
(third trimester). A list of chronic disorders was also pre-
sented to the respondents, including cardiovascular and
rheumatic disorders, diabetes and epilepsy, and an open-
ended option. Furthermore, the women were presented
with a question on sick leave during pregnancy (dichoto-
mised yes/no).
In addition to the standardised questions about medi-
cine use for specific illnesses, the respondents were
questioned about over-the-counter (OTC) medicine use
during pregnancy, including OTC medicines against
nausea, and the timing of use. A medicine was defined
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as a single product containing one or more active in-
gredients. The main active ingredient(s) and formula-
tion of the branded medicinal product were identified
for each specific trademark name and recorded using
either the national medicine database or the Martindale
textbook [24]. All medicines were then coded into the
corresponding Anatomical Therapeutic Chemical (ATC)
codes in accordance with the World Health Organization
(WHO) ATC index [25]. Whenever possible, the 5th level
of the ATC was used.
Any use of herbal medicines was specifically requested,
including the name of the product, reason for its use,
and the timing of use during pregnancy. The name of
the herbal medicine and the reason for its use were re-
ported as free-text entry fields. Herbal medicine could
also be reported under the disease-specific questions
and the questions about OTC medicine. Herbal medi-
cines were identified by name and coded in accordance
with a pre-determined list of herbs [26].
The respondents were classified as having nausea dur-
ing pregnancy if they reported having had nausea when
questioned about short-term illnesses, if they reported
any use of OTC medicines against nausea, or if they gave
nausea as an indication for the use of herbal or homeo-
pathic medicines.
Sociodemographic and lifestyle variables
The following variables were explored in relation to nau-
sea and the use of conventional medicines: region of
residence, maternal age, parity, marital status, education,
working status, smoking during pregnancy, use of folic
acid, and multiple pregnancy. Sociodemographic vari-
ables were categorised as presented in Table 1.
Measurements of maternal mental health
Symptoms of depression were measured by the Edinburgh
Postnatal Depression Scale (EPDS), a self-rating 10-
item scale initially developed by Cox et al. to detect
postnatal depression [27]. However, the scale has also
been validated as a screening tool for major depression
in pregnant women with satisfactory results and has
been used in several studies in various countries [28].
Cut-off scores of 11, 10 and 10 applied at weeks 12, 24,
and 36 of pregnancy, respectively, resulted in 79 %, 70
%, and 76 % sensitivity, respectively, and 97 %, 96 %,
and 94 % specificity, respectively [28]. Each question
has four different options scored as 0, 1, 2, or 3. The scale
rates the intensity of depressive symptoms over the previ-
ous 7 days. The total score ranges between 0 and 30. Hav-
ing symptoms of depression was defined as having a total
EPDS score ≥13 [27]. Validated translated versions of the
original EPDS were available for eight languages other than
English: Dutch, French, German, Icelandic, Norwegian,
Slovenian, Spanish, and Swedish [29]. The Serbian version
was developed by two independent linguistic experts, who
carried out translations and back-translations. Any discrep-
ancies between the back-translated and original EPDS were
identified and corrected. For the remaining five languages,
the translated versions used in previous studies were uti-
lised [30–33].
Statistical analysis
Descriptive statistics were used to calculate the preva-
lence of conventional and herbal medicines use against
nausea during pregnancy and presented as percentages.
Univariate and multivariate generalised estimating equa-
tion (GEE) analyses were performed to explore potential
significant associations between the maternal character-
istics listed in Table 1 and the use of conventional medi-
cines against nausea. The GEE with the binary logistic
model was used to correct for clustering on region of
residency. Odds ratios (ORs) are presented with 95 %
confidence intervals (CIs). All variables in Table 1, with
the exception of multiple pregnancy, were included in
the multivariate models.
Univariate and multivariate GEE analyses were also used
to explore the relationships between co-morbidity and
nausea and its treatment. First, univariate analyses were
performed. Then full multivariate models were built in-
cluding all variables presented in Table 1. Reduced models
were fit by excluding non-significant variables (signifi-
cance level: p < 0.05), unless removal of the variable
caused a >10 % change in the effect estimates. Sub ana-
lyses including the EPDS were restricted to pregnant
women only, as the EPDS is based on symptoms during
the prior week. Moreover, stratified analyses on timing of
gestation (during first trimester versus after first trimester)
were performed when studying the association between
nausea and comorbidity.
All statistical analyses were performed using Statistical
Package for the Social Sciences (SPSS) version 20.0 (IBM
SPSS Statistics 20) for Windows (SPSS, Chicago, IL, USA).
Ethics
Before entering the online questionnaire, the respondents
had to 1) read the study description in which the study
objectives, the participants’ right to withdraw at any time,
and contact persons in the applicable country were pre-
sented, and 2) answer the following question: “Are you
willing to participate in the study?” If the woman ticked
“yes” as the answer it was considered informed consent.
The study was approved by the Regional Ethics Com-
mittee, Region South-East in Norway, and the relevant
Ethics Boards in each specific country when required
[23]. Complementary ethical approval was required and
obtained from the Faculty of Medicine and Health Sci-
ence Research Ethics Committee of the University of
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East Anglia in the UK, The National Bioethics Commit-
tee in Iceland and The Scientific Ethic Board, Provincial
Health Service of Trento in Italy.The STROBE state-
ments were used when writing this paper (Additional
file 1).
Results
During the 2-month study period in each country, a
total of 9113 women were included in the study. Re-
spondents who were residents of Europe (Western, n =
3201; Northern, n= 2820; Eastern, n = 2342) constituted
the largest proportion of the total study population, followed
by North America (n = 533) and Australia (n = 217).
At the time of completing the questionnaire, 4938
(54.2 %) of the women were pregnant and 4175 (45.8 %)
had given birth during the previous year. Among the
pregnant respondents, 1067 (21.6 %), 1656 (33.5 %), and
2214 (44.8 %) were in the first, second, and third trimes-
ter of their pregnancy, respectively, and 182 (3.7 %) were
less than 6 weeks pregnant. A total of 1913 (45.8 %) of
the mothers had an infant less than 24 weeks of age.
Among the respondents, 6701 (73.5 %) had experienced
nausea during pregnancy; 1828 (27.3 %) used some form
of treatment against nausea and 4873 (72.7 %) did not.
Conventional medicines against nausea were used by
1201 (17.9 %) of the women and herbal medicines by
556 (8.3 %).
Both the prevalence of nausea and its treatment varied
by country and region (Table 2 and Fig. 1). The prevalence
of nausea ranged from 62.0 % in Russia to 84.5 % in
Iceland. The proportion of respondents treated among
those who suffered from nausea ranged from 10.4 % in
Finland to 53.2 % in France; the next highest propor-
tions were in Switzerland (48.9 %), Canada (48.0 %),
Table 2 Most common treatments against nausea by region and country










n (%) n (%) n (%) (n) n (%) (n)
Western Europe (n = 3201) 2338 (73.0) 736 (23.0) 449 (14.0) Antihistamines (174) 230 (7.2) Ginger (203)
Austria (n = 82) 54 (65.9) 15 (18.3) 7 (8.5) Antihistamines (3) and
metoclopramide (3)
8 (9.8) Ginger (8)
France (n = 374) 263 (70.3) 140 (37.4) 101 (27.0) Metoclopramide (43) 7 (1.9) Ginger (3)
Italy (n = 926) 645 (69.7) 193 (20.8) 77 (8.3) Metoclopramide (25) 80 (8.6) Ginger (71)
The Netherlands (n = 81) 58 (71.6) 14 (17.3) 12 (14.8) Antihistamines (8) 3 (3.7) Ginger (3)
Switzerland (n = 618) 436 (70.6) 213 (34.5) 165 (26.7) Antihistamines (118) 49 (7.9) Ginger (43)
United Kingdom (n = 1120) 882 (78.8) 161 (14.4) 87 (7.8) Antihistamines (35) 83 (7.4) Ginger (75)
Northern Europe (n = 2820) 2259 (80.1) 533 (18.9) 417 (14.8) Antihistamines (316) 112 (4.0) Ginger (107)
Finland (n = 574) 453 (78.9) 47 (8.2) 37 (6.4) Metoclopramide (17) 3 (0.5) Ginger (3)
Iceland (n = 71) 60 (84.5) 26 (36.6) 17 (23.9) Antihistamines (12) 12 (16.9) Ginger (11)
Norway (n = 1288) 1028 (79.8) 199 (15.5) 120 (9.3) Antihistamines (74) 95 (7.4) Ginger (92)
Sweden (n = 887) 718 (80.9) 261 (29.4) 243 (27.4) Antihistamines (219) 2 (0.2) Ginger (1) and
black pepper (1)
Eastern Europe (n = 2342) 1512 (64.6) 303 (12.9) 146 (6.2) Antacids (56) 121 (5.2) Ginger (69)
Croatia (n = 286) 182 (63.6) 27 (9.4) 14 (4.9) Antacids (5) 1 (0.3) Other herbal
products (1)
Poland (n = 679) 447 (65.8) 81 (11.9) 37 (5.4) Antihistamines (16) 43 (6.3) Ginger (36)
Russia (n = 1008) 625 (62.0) 146 (14.5) 81 (8.0) Antacids (29) 59 (5.9) Artichoke (28)
Serbia (n = 220) 144 (65.5) 29 (13.2) 13 (5.9) Antacids (7) 0 -
Slovenia (n = 149) 114 (76.5) 20 (13.4) 1 (0.7) Antacids (1) 18 (12.1) Ginger (16)
North-America (n = 533) 415 (77.9) 171 (32.1) 137 (25.7) Antihistamines (96) 46 (8.6) Ginger (41)
Canada (n = 236) 177 (75.0) 85 (36.0) 74 (31.4) Antihistamines (68) 19 (8.1) Ginger (18)
USA (n = 297) 238 (80.1) 86 (29.0) 63 (21.2) Ondansetron (29) 27 (9.1) Ginger (23)
Australia (n = 217) 177 (81.6) 85 (39.2) 52 (24.0) Metoclopramide (32) 47 (21.7) Ginger (46)
Total population (n = 9113) 6701 (73.5) 1828 (20.1) 1201 (13.2) Antihistamines (613) 556 (6.1) Ginger (466)
aIncluding conventional medicines, herbal medicines, homeopathic medicines and dietary supplements
Antacids are defined as all medicines with ATC-code A02
Antihistamines are defined as all medicines with ATC-code R06
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and Australia (48.0 %). In 11 countries the treatment
rates were below 30 % (Fig. 1). Among the regions,
Australia (48.0 %) and North America (41.2 %) had the
highest rates of treatment.
The most commonly used conventional medicines
against nausea in the total population were antihistamines,
which were used by 613 respondents (6.7 %) (Table 2 and
Additional file 2). Metoclopramide was the second most
commonly used medicine with 268 respondents (2.9 %).
Antacids (ATC-group A02), ondansetron, and domperi-
done were used by 176 (2.6 %), 54 (0.6 %), and 48 (0.5 %)
respondents, respectively. Conventional medicines were
most commonly used against nausea in Canada, France,
Switzerland and Sweden. The type of conventional
medicine most commonly used among women with nau-
sea differed by region and country, but in the majority of
countries it was either antihistamines or metoclopramide.
An exception was ondansetron, which was the most com-
monly used medicine in the United States, closely
followed by antihistamines. In Croatia, Russia, Serbia, and
Slovenia the most common medicines were antacids, des-
pite heartburn and reflux problems being less prevalent in
these countries (60.5 %, 59.6 %, 52.7 %, and 57.7 %, re-
spectively) compared to the total population (66.0 %). The
countries in Eastern Europe had a low frequency of con-
ventional medicines use. One respondent from Slovenia
reported the use of conventional medicines. Interestingly,
metopimazine was reported to be used against nausea by
Fig. 1 Use of treatment against nausea among women experiencing nausea
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29 respondents, all in France. In Canada, 54 respondents
had used Diclectin®, which is a combination of the antihis-
tamine doxylamine and pyridoxine.
Among the five regions, Australia had the highest fre-
quency of herbal medicine use (21.7 %). Ginger was the
most commonly used herbal medicine in the total popu-
lation (5.1 %) and in most regions and countries. How-
ever, in Russia the most commonly used herbal medicine
was artichoke (2.8 %). In most countries, herbal medicines
were used to a lesser extent than conventional medicines,
with the exception of Slovenia, Poland, Austria, and Italy.
Maternal characteristics as predictors of nausea and
the use of conventional medicines against nausea during
pregnancy are shown in Table 1. Respondents who had
more than one previous live birth, worked as health care
personnel, or were unemployed were more likely to ex-
perience nausea, whereas respondents who used folic
acid during pregnancy only or smoked during pregnancy
were less likely to experience nausea according to ad-
justed models. Respondents who had primary school as
their highest completed education, were health care
personnel, or had used folic acid before the pregnancy
were more likely to have used conventional medicines
against nausea than respondents with characteristics
within the respective reference categories. Multiple
pregnancy was also associated with use of medicines
against nausea.
Women who experienced nausea during pregnancy were
more likely to have any of the acute short-term illnesses
listed in Table 3. These respondents were also more likely
to have four or more co-morbidities in terms of acute
short-term illnesses, any chronic illness, or to have taken
sick leave during pregnancy. This pattern was similar when
comparing respondents who had nausea and used conven-
tional medicines against nausea to the respondents who
experienced nausea without using any treatment. How-
ever, the effect estimates were generally lower than for
nausea alone. Sub analyses including only respondents
pregnant at the time of participation in the study re-
vealed that respondents who experienced nausea were
more likely to have symptoms of depression (EPDS
score ≥13) than respondents without nausea. This was
also true among respondents who had nausea and used
conventional medicines compared to respondents who
experienced nausea without treatment.
In an additional sub analysis we found that time of ges-
tation acted as a plausible effect modifier of the associ-
ation between medicated nausea and comorbidity.
Specifically, respondents early in their pregnancy (≤1 tri-
mester) who treated nausea with conventional medicines
presented a significant 3.1-, 2.8-, and 2.1-fold increased
likelihood of taking sick leave (crude OR: 3.1, 95 % CI:
1.8-5.5), having depressive symptoms during pregnancy
(crude OR: 2.8, 95 % CI: 1.7-4.6), and having heartburn
and reflux problems (crude OR: 2.1, 95 % CI: 1.6-2.6), re-
spectively, compared to respondents with non-medicated
nausea. Such measures of association were of a much
smaller magnitude (30-70 % increased likelihood) in the
stratum comprising only respondents later in their preg-
nancy (>1 trimester). Similar results were observed when
respondents with nausea were compared to those without
nausea (data not shown).
Discussion
Variations were found across countries and regions in the
prevalence of nausea, treatment rates, and types of treat-
ment used against nausea during pregnancy. Cultural differ-
ences reflected in different treatment traditions, differences
between countries with respect to the women’s and general
practitioners’ willingness to treat, and variations in access
to prenatal care and treatments and their relative costs may
explain several of our findings. Among respondents suffer-
ing from nausea, less than one in three used any form of
treatment, and only 18 % had used any medicine against
this complaint. We do not have data on the severity of
nausea, and the respondents may generally suffer from
mild symptoms that are sufficiently managed by non-
pharmacological treatments, such as dietary changes.
However, the low prevalence of treatment may also be ex-
plained by a reluctance of many general practitioners to
treat these women [34], or by an overestimation of the risk
of medicines among pregnant women with nausea [35].
The overall prevalence of nausea (73.5 %) in this study is
in accordance with a recent meta-analysis of NVP includ-
ing 59 studies from various countries [1].
Canada, followed by France, Switzerland and Sweden,
had the highest prevalence of conventional medicines use
against nausea. This finding may be due to the clear and
well known guidelines in this country [36, 37] and the an-
tiemetic Diclectin®, which is approved for use against
NVP. Therefore, simplifying the identification of safe and
effective treatments may possibly increase the use of treat-
ment. Among the European countries, medicine use was
highest in France, which is in line with the results of a
study of drug utilisation in pregnancy that included six
European Registries of Congenital Anomalies in four
European countries: France, Great Britain, Italy, and the
Netherlands [38]. The authors of the study found that the
two centres in France had the highest prevalence of medi-
cine use (80.8 % and 74.2 %), and that antinauseants were
the most frequently consumed drugs in this country (20.9
% and 15.0 %) [38]. We found that several French respon-
dents used metopimazine, a dopamine antagonist, which
was not reported in any of the other countries. This find-
ing is in accordance with a comparative study by Einarson
and colleagues in 1998 in which France was the only
country to list metopimazine as a treatment option [14].
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In Sweden, antihistamines were the most frequently used
medicines against nausea, which is also in line with previ-
ous findings [17].
Antihistamines and metoclopramide were the most
commonly used conventional medicines against nausea
in the vast majority of the countries. The exceptions
were the USA, Croatia, Russia, Serbia, and Slovenia,
where ondansetron (USA) and antacids (Croatia, Russia,
Serbia, and Slovenia) were the most commonly used
medicines against nausea. This is in line with findings of
a study of hyperemesis gravidarum treatments detecting
inter-country variations of frequency of different treat-
ments of which serotonin inhibitors were most fre-
quently used in the USA, antihistamines in Canada,
whereas Australia had the highest reported use of pro-
motility agents such as metoclopramide [39]. Meta-
analyses and epidemiological studies have not found a
higher risk of malformations with antihistamines and
metoclopramide [40–43], and antihistamines are
regarded as a first line treatment according to guide-
lines in both North America and Europe [36, 37, 44–
46]. Recently, the safety of metoclopramide and ondan-
setron has been questioned [47, 48]. In July 2013, the
European Medicines Agency (EMA) recommended
changing the use of metoclopramide to 10 mg three
times a day up to 5 days to reduce the risk of extrapyr-
amidal side effects [48]. As this is seldom long enough
to treat NVP, the change will limit this medicine’s use-
fulness for nausea and vomiting in the pregnant popula-
tion. In 2011, the U.S. Food and Drug Administration
(FDA) raised concerns over cardiovascular safety, suggest-
ing that ondansetron could cause prolonged QT interval,
which can lead to Torsade de Pointes [49]. Electrocardio-
gram (ECG) monitoring in patients with electrolyte abnor-
malities is advised. A recent Danish registry study of
ondansetron use during the first trimester did not detect
any increased risk of malformations [50]. Another unpub-
lished study based on the same registries detected a 2-fold
increase in the prevalence of major congenital heart de-
fects after exposure to ondansetron [51]. Notably, the data
in our study were collected during winter 2011–2012.
Therefore, the medication utilisation pattern may have
changed due to the warnings issued by the EMA (2013)
and FDA (2011) with respect to metoclopramide and
ondansetron, respectively.
Australia had the highest rate of herbal medicine use
against nausea, followed by Iceland and Slovenia. Australia
has previously been reported to have a high prevalence of
herbal medicine and CAM use in pregnancy in general [52,
53], and also more specifically a high use of ginger during
pregnancy [52]. The results with respect to Slovenia were
special; 12.1 % of respondents had used herbal medicine,
but only one respondent had used a conventional medicine
against nausea. This finding may indicate a long tradition
of herbal medicine in Slovenia or a lack of access to con-
ventional medicines.
Ginger was the dominant herbal medicine used against
nausea. Ginger has been reported to be more effective
than placebo and equally effective as vitamin B6 and di-
menhydrinate against nausea in pregnancy [54]. With re-
spect to safety, a cohort study with 1020 ginger-exposed
pregnancies (466 in the first trimester) found no increased
risk of malformations, stillbirth/perinatal death, low birth
weight, preterm birth, or low Apgar score [16]. Russia was
the only country to report the use of artichoke against
nausea. However, no studies of artichoke use in pregnancy
were found, though artichoke has been observed to have
an antiemetic effect in outpatients with dyspeptic syn-
drome [55].
Various maternal characteristics were associated with
nausea and its treatment. Having more than one previ-
ous live birth was associated with nausea, probably be-
cause having additional children results in less time to
rest and relieve the nausea. This finding is in accordance
with previous research [56, 57], but the data are conflict-
ing [4]. Other factors associated with nausea were work-
ing as health care personnel or being unemployed, which
is in line with previous research that found an association
between being a housewife or out of work and nausea
[57, 58]. Respondents who smoked during pregnancy or
who used folic acid during pregnancy were less likely to
report nausea. Decreased risk of nausea among smokers
was observed in several earlier studies [4, 56, 57]. Use of
vitamins in early pregnancy was previously found to be
protective against nausea [57, 59]. Women who take folic
acid before, as well as during, pregnancy are most likely
planning to become pregnant, and this may imply that
they are more attentive to early symptoms of pregnancy
than women who use folic acid only during pregnancy.
Respondents who had a lower education were more
likely to use medicines against nausea. This finding is
in accordance with a Swedish study [17]. Respondents
working as health care professionals were also more
likely to use medicines against nausea, which can be ex-
plained by this group being aware of safe and effective
treatment options for nausea. Multiple pregnancy was
associated with the use of medicines. This may indicate
that use of medicines may act as a marker of severe
forms of nausea, as it is previously found that multiple
pregnancy increase the risk of nausea [56]. In addition,
the severity of NVP symptoms has been associated with
the use of antiemetics [7, 60].
We found a high burden of co-morbidity among re-
spondents experiencing nausea during pregnancy. The
association with symptoms of depression and sick leave in
particular warrants attention. Women who suffer from any
pregnancy-related complaint may tend to seek information
on the internet to a greater extent than women who feel
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well. Therefore, the respondents may be seeking informa-
tion and responding at the peak of their discomfort. How-
ever, symptoms of depression have also been associated
with nausea during pregnancy [7, 9, 60]. Similarly, the asso-
ciation with heartburn and reflux problems is in agreement
with previous studies [61]. Clinicians should be aware of
the high degree of co-morbidity with nausea and routinely
ask women with nausea whether they have reflux problems
or other pregnancy-related ailments.
Our findings indicate that women who have nausea in
early pregnancy, especially those who treat nausea with
medicines, have a high likelihood of experiencing depres-
sive symptoms, heartburn and reflux problems, and taking
sick leave. This is an important clinical finding and em-
phasises how debilitating nausea during pregnancy can be
for these women. General practitioners in contact with
women with NVP should be aware of the high degree of
co-morbidity, examine these women for symptoms of de-
pression and heartburn and reflux problems, and treat
these conditions if present. Special attention should be
paid to women in early pregnancy. Treating heartburn
and reflux problems may alleviate symptoms of NVP and
increase the women’s wellbeing [62]. Major guidelines
suggest antacids as adjunctive therapy against NVP [36,
37, 44].
This study has several strengths and limitations that
should be acknowledged. This is the first multinational
study to simultaneously collect data on the prevalence of
nausea and its treatment, which enables direct compari-
sons between countries and regions. A large number of
women from a variety of countries in different regions of
the world were reached due to the utilisation of a web-
based questionnaire posted on various pregnancy-related
websites. These data provide valuable insights into the
prevalence of nausea and the treatment of this complaint
across countries and regions. Furthermore, the study
population was reasonably comparable to the general
birthing population with respect to age, parity, and smok-
ing habits, though the women in the study population had
a higher education on average [23]. However, the possibil-
ity that the respondents differ from the general birthing
population in ways that our analysis cannot control for
cannot be excluded. In some of the countries (Australia,
Canada, France, Russia, the Netherlands, and the USA),
the study sample was a small proportion of the general
birthing population. For these specific countries, our find-
ings should be generalised with caution.
There are some other limitations that need to be ad-
dressed. First, a conventional response rate could not be
calculated because the questionnaire was only accessible
through websites. However, epidemiological studies have
indicated that web-based recruitment methods have rea-
sonable validity [63, 64]. In addition, women of childbear-
ing age generally have a relatively high internet penetration
rate [65–67]. The fact that we found a prevalence of nausea
very similar to the prevalence reported in the literature,
and that the comparison with the birthing population in
each participating country had high external validity, sup-
ports our approach. However, the higher education of the
respondents may have had an impact on their choice of
treatment. Second, including women at an early stage in
their pregnancy may underestimate the prevalence of nau-
sea, as this complaint often does not occur before gesta-
tional weeks 6–8. However, this only applies to the 182
women (2.0 %) who were less than 6 weeks pregnant at the
time of participation. Thirdly, although we tried to minim-
ise the risk of recall bias by excluding women with a youn-
gest child aged >1 year, this risk cannot be ruled out. In
addition, the EPDS was only measured at one time point
during the pregnancy and two time points are considered
more valid [29]. Finally, we lack information on the severity
of nausea and our results should be interpreted with these
limitations in mind.
Conclusions
The prevalence of nausea was high across all participating
countries, but its treatment varied, possibly due to cultural
differences and differences in attitudes towards medicines.
Women who reported nausea also had a high burden of
co-morbidity, especially heartburn and reflux symptoms.
The association with symptoms of depression and sick
leave warrants attention. These findings will be helpful to
health care personnel involved in the care of pregnant
women with nausea.
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Key points:  
Nausea and vomiting during pregnancy (NVP) is very common, and of clinical significance for 
35% of the women.  
 While the GPs agreed on the importance of normalising the symptoms, the women felt 
their distress was trivialised, and missed being properly evaluated.  
 Both the GPs and the women showed a reluctant attitude to medical treatment of NVP. 
 The GPs gave the impression of only considering medical treatment after progression of 













Objective: Nausea and vomiting during pregnancy (NVP) is very common, and may have great 
impact on a woman’s life. The aim of this study was to explore thoughts and attitudes among 
Norwegian pregnant women and GPs on treatment of NVP and pregnancy care.  
Design: Focus group study.  
Setting and subjects: Separate focus group discussions were conducted with pregnant women and 
GPs. 
Results: Two focus group discussions were conducted with pregnant women and two with GPs. 
The GPs thought it was important to normalise NVP symptoms. However, the women felt their 
distress due to NVP was trivialised by the GPs. The women were sceptical towards medicines use 
while pregnant, and avoidance was sought despite being ill. The GPs appeared uncertain with 
respect to medical treatment of NVP, which was expressed to only be considered after 
progression to quite severe symptoms. Sick leave seemed to be an important part of the treatment 
regime applied by the GPs. The women had good experiences with graded sick leave. 
Conclusion: This Norwegian study identifies attitudes among GPs and pregnant women that may 
act as obstacles to appropriate care for women with NVP. The pregnant women and the GPs 
seemed to talk at cross purposes; GPs normalisation of the symptoms made the women feel their 
distress due to NVP was trivialised by the GPs. Our results indicate that pregnant women with 
NVP requiring medical treatment probably need comprehensive reassurance of no evidence of 
risk, before considering using any medicines.  
Key words: nausea, vomiting, pregnancy, therapeutics, general practice 
Background 
Nausea affects around 70% of pregnant women [1]. Approximately 50% experience additional 
vomiting [2, 3]. Symptoms typically initiate during pregnancy week 6-8, peaking around week 
11-13 and subside within week 16 [2, 3]. The prevalence of hyperemesis gravidarum (HG), the 
most severe form of nausea during pregnancy, is about 1% [4]. HG is characterised by 
dehydration and electrolyte imbalance, and often leads to hospitalisation [5]. 
Though some women privately celebrate the symptoms of nausea as one of the first signs of a 
longed-for pregnancy [6], prolonged nausea and vomiting during pregnancy (NVP) can be very 
debilitating for the women. For about 35% of the women, NVP is clinically significant [2, 5]. 
NVP severely reduces the women’s quality of life, and feelings of isolation and helplessness are 
reported [7-9]. The ability to carry out daily activities is impaired, including parenting, partly due 
to less interaction with their children [9]. Women report that NVP adversely affects social 
functioning, relationship with partner, and also their partner’s daily life [9, 10]. Additionally, it 
leads to consumption of resources in the health care system, and increased socio-economic costs 
with increasing severity of NVP [11, 12]. NVP is one of the main reasons for being on sick leave 
during pregnancy, reported to be responsible for almost one third of total sick leave during 
pregnancy [13]. In Norway, as an employee, you are entitled to sickness benefits if you are 
occupationally disabled due to own illness or injury and fulfil the demands to an employee as set 
by The Norwegian Labour and Welfare Administration (Norwegian short name: NAV) [14]. Sick 
leave certificates can be issued by physicians. You get sickness benefits equivalent to full wages 
(up to a set amount), paid by your employer the first 16 calendar days, and then by NAV [14]. 
The sick leave may be full time or graded (partial). The pregnancy care program in Norway is 
free of charge and pregnant women are entitled to nine routine consultations with either their GP 
or a midwife, and additional consultations if required [15]. 
General practitioners (GPs) in the UK are alleged to be reluctant to the use of treatment against 
NVP [16]. Given that NVP is one of the most commonly experienced pregnancy complaints, and 
most often self-limiting, women presenting with NVP may not always be taken seriously. 
Canadian and American guidelines recommend early treatment of the symptoms of NVP to 
reduce costs related to hospitalisations, contacts with pregnancy care units, and sick leave, 
arguing that early symptoms are easier to treat [17, 18]. Given that NVP is most commonly 
experienced during the first trimester, and consequently during organogenesis, many women and 
prescribers may be reluctant to the use of medications to treat this complaint. This is reflected in 
a study from the USA reporting that only 15% of women suffering from NVP used any 
pharmacologic treatment [19]. Insufficient safety data, preference for non-pharmacologic 
methods and being made to feel uncomfortable by the physician are reported as common reasons 
for not using medicines against NVP among Canadian women [20]. It is well known that 
pregnant women often overestimate the risk of medications during pregnancy [21, 22]. Various 
Norwegian treatment guidelines for NVP exist [23-26], but no medicines have NVP as an 
approved indication in Norway, which further complicates the picture.  
The aim of this study was to explore the thoughts and attitudes among Norwegian pregnant 
women and GPs on treatment of NVP and pregnancy care.  
Design, material and methods 
A focus group study was conducted with two groups of pregnant women during November - 
December 2012 and two groups of GPs during December 2013. Women attending routine 
ultrasound examination in pregnancy week 17-18, and who had experienced NVP in current 
pregnancy, received an information brochure together with an invitation to the study. Snowball 
recruitment was also used as a strategy due to slow response among pregnant women at the 
antenatal clinic. At time of participation, all women were still pregnant. In total, 10 women were 
recruited and distributed in two focus groups of four and six participants, respectively (Table 1). 
The discussions lasted approximately 60 minutes. The women were asked to tell about their own 
thoughts on and experiences with pregnancy care and treatment of NVP. 
To recruit GPs, educational groups for authorised and practicing GPs under specialisation in 
general practice were contacted via e-mail. Slow recruitment was also experienced with respect 
to this source population. Two focus group discussions were conducted, each lasting 60 minutes, 
with five GPs in each group (Table 1). The GPs were asked to talk about their experience with 
and thoughts on treatment of NVP. 
All focus group discussions were conducted according to an interview guide to facilitate open 
discussion on pre-identified themes [27]. Separate interview guides were developed specifically 
for the pregnant women and the GPs. However, divergences from the interview guides occurred 
to facilitate a natural conversation in the group. Three of the authors acted as group moderators 
(HCS, IHS, LH), and one co-moderator in each group took field notes. The focus group 
discussions were audio-recorded and transcribed verbatim. The transcripts from the focus group 
discussions with the GPs and the pregnant women were analysed separately, according to the 
principles of systematic text condensation as described by Malterud [28]. Firstly, the transcripts 
were read as a whole by three of the authors to establish an overview of data, followed by the 
identification of preliminary themes representing different aspects of the participants’ thoughts on 
and attitudes to treatment of NVP. Collaborative negotiation strategy was applied. Secondly, 
meaning units (a text fragment that contains information about the research question) were sorted 
under the appropriate themes or code groups. Thirdly, the content of the coded groups was 
reduced into a condensate aiming to capture the essence of the meaning units. Lastly, descriptions 
and concepts were developed based on the condensates.  
The study was approved by the Regional Committee for Ethics in Medical Research, Region 
West, and the Norwegian Data Inspectorate. 
 
Results 
The pregnant women 
A call for acknowledgement 
The women felt that their NVP was trivialised by their GP. Even after it was emphasised that 
NVP strongly impaired daily life functioning and general wellbeing, the women were told that 
symptoms of nausea are completely normal and expected as part of being pregnant. The women 
felt they weren’t taken seriously, and missed acceptance and acknowledgement from their GP of 
how debilitating NVP is to live with. Impact on social life and work situation was mentioned. 
One woman also said it was hard not being fully able to care for her other children who were too 
young to understand why their mother couldn’t play with them.  
 “I told my GP that I was very bothered with nausea. However, he just responded that 
nausea is very normal, and that all pregnant women had it just like me. Nothing to worry 
about. Even when I tried to emphasise on the huge impact the nausea had on my daily life, 
I just got the impression that it was as expected.” (W5) 
Furthermore, they missed being evaluated properly for the severity of their symptoms, and 
wanted to be asked about their general well-being, weight and diet. A close follow-up was a 
request from many of the participants.   
Inconsistent information resulted in scepticism and insecurity 
Information on treatment of NVP was sought from numerous sources; GPs, pharmacies, internet, 
family and friends. Family, especially mothers, was a good source of advice on folk remedies. 
However, the women experienced a generational gap, themselves being more sceptical to folk 
remedies than their mothers or grandmothers. Though advice from pregnancy fora on the internet 
was taken with a pinch of salt, it could be used as an idea bank. Health care personnel were 
considered the most trustworthy source of information, and medical advice anchored in evidence-
based medicine was expected. However, the experience of many of the participants was that 
information on treatment was inconsistent between different health care personnel, which made 
the participants feel frustrated, scared and insecure. 
“You shouldn’t be given many different answers [from various healthcare personnel]. 
You are sceptical and insecure to begin with thinking that you are carrying something in 
your belly that you may harm. If you ask around for advice and get many different 
answers, this is very frustrating and annoying.” (W1) 
 
Feelings of guilt 
A healthy life style, including a healthy diet and regular exercise, was recognised by the 
participants as important during pregnancy. However, a strict focus on this by health care 
personnel while the women were suffering from NVP, made the participants feel guilty due to not 
being able to fulfil these expectations. When they felt sick, they had to eat or drink whatever they 
could handle, even if this meant less healthy types of food and drinks, like crisps and soft drinks.  
“One might say that focus on a healthy diet is important, but I think most pregnant women 
know what you should or should not eat. In this condition it is all about what I actually am 
able to eat. It would feel good to be met by health care personnel that understand this.” 
(W6) 
 
One woman emphasised that she was worried about the baby, and that it was reassuring to be told 
that the foetus’ needs are fulfilled despite the mother not eating much.  
“My doctor told me that no matter how often you vomit, the baby inside you takes what it 
needs, anyway. That is good to hear, because when I came to the ultrasound appointment 
in week seven or whatever, I had pictured a starved little lemon inside me.” (W2) 
 
Medicines – something for others, not for me 
The participants were generally very sceptical to medicines use while pregnant. Avoidance was 
sought due to fear of teratogenic effects with references to the Thalidomide tragedy during the 
60’s. Some of the participants had the impression that also the GPs are reluctant to treat NVP 
with medicines due to fear of teratogenic effects, in contrast to their experience with the specialist 
health service who prescribed medicines when needed. Though the participants themselves had 
made the decision not to use medicines, they made it clear that they realised that the choice of 
treatment of NVP is individual. The question of treatment seemed to depend on how much one 
can bear of the nausea’s negative impact on social, occupational and daily life functioning, with 
the threshold set generally high.  
 “I do not feel like medicating my discomfort, not when I can actually manage to eat at 
least something.[…]. But I do not have anything against others who want to medicate 
their nausea, or who are in need of medicines. Because I cannot know other people’s 
needs, I only know what is right for me. […] I would never forgive myself if something 
happened to the baby just because I couldn’t stand the nausea.” (W6) 
In contrast to the reluctance to use medicines, one woman, who had HG for the second time, 
thought that the GPs were too restrictive and that they delayed the use of medicines too long.  
“Women lose a lot of weight and get dehydrated. I don’t think it should be like that 
considering you are carrying a child. I think it is important to have some quality of life 
despite having NVP.” (W8) 
 
Graded sick leave - something that is helpful 
Most of the participants had been on sick leave due to their NVP. They had good experience with 
sick leave as helpful to reduce stress which was experienced as a trigger. Managing to keep a part 
time position, however, was emphasised as positive, as this enabled some social contact. To get 
off the couch and to think of other things than NVP for a while could be helpful. Otherwise, as 
one woman said, you will easily feel isolated, and a bit blue. 
 “I think that, if one can manage, it would be best to be on graded sick leave. To be able to 
get some social input. And to get something out of the day, and get your thoughts on to 
something other than nausea. Because you get very easily focused on the nausea lying on 




The GPs pointed out that due to NVP being one of many subjects on the list for the first 
pregnancy consultation, there is limited time to ask follow-up questions on how the pregnant 
women are handling their NVP. A box is typically ticked if nausea is confirmed, and unless the 
women have specific questions, the subject is left at that. If the women expressed concern with 
regards to NVP, the participants highly agreed on the importance of normalising the condition 
and assuring the woman that it is not harmful and not a disease.  
“I think it is very important to normalise it. NVP is not a disease, it is something to be 
expected while being pregnant.” (GP2) 
 
The dilemma of prescribing sick leave– appraised by the women, criticised by NAV 
Sick leave was presented as a dilemma. A scenario, having the Norwegian Labour and Welfare 
Administration (NAV) on one side, demanding a more restrictive policy for sick leave, and the 
women on the other side, begging for sick leave, was described. They were also afraid that they 
might lose the patient if they denied the woman to go on sick leave.  
“According to NAV it’s all about the observations you do.[…] But that’s the “NAV-
world”, and we work in another world. Our job is to build a relationship based on trust. If 
we had to doubt all patients who come and tell this kind of stories, it won’t work out.” 
(GP6) 
 Participants expressed a wish for an objective instrument to measure symptoms of NVP as 
supportive documentation of the reason for issuing sick leave.  
The participants had generally a low threshold to prescribe sick leave, if the women were 
struggling with NVP. It was spontaneously mentioned by the participants when they were 
discussing treatment of NVP in general, giving the impression of sick leave being viewed by the 
GPs as one of the first interventions which was tried against NVP when action had to be taken, 
often without concomitant prescription of medicines.  
“I don’t think I have experienced that a tablet is what enable them to go to work. The 
result is sick leave anyway. They have sometimes been given a prescription in addition, to 
relieve the symptoms.” (GP3) 
 
Treatment with medicines is the next step – or is it? 
When the participants were asked about interventions against NVP, they all agreed that advice on 
dietary and life style changes was a natural starting point, and something they seemed to be 
confident of giving. However, in their experience such measures were not of much help. 
“A woman with NVP, had tried everything, and nothing helped. She had biscuits on the 
night table, eating just after waking up in the morning etc.. It didn’t exactly provide her 
with much relief.” (GP8) 
The GPs expressed reluctance to use of medicines in the treatment of NVP. However, if dietary 
and life style changes and/or sick leave were insufficient, the participants seemed to agree on 
medicines being the next step. Medicines were only considered if the woman had too much time 
lost from work, or was close to admission to hospital due to NVP.  
”Treatment is something that is being considered if the condition evolves to a great extent, 
but before the women are admitted to hospital due to electrolyte imbalance. When you 
feel you are in that phase where admission to hospital needs to be prevented”. (GP2) 
“Mmmhm.” (GP3, GP4, GP5 nodding in agreement.) 
It was expressed that they did not feel comfortable prescribing medicines against NVP due to the 
awareness of the teratogenic potential of use of medicines during first trimester, with references 
made to Thalidomide. Some of the GPs also agreed that they didn’t believe in the effect of 
medicines against NVP. 
“You may try very carefully with medications with no promise to the women that this is 
final quick-fix. They may as well not work.” (GP5) 
One GP even claimed that the cases which needed pharmacological treatment should be referred 
to the hospital and, consequently, that pharmacological treatment of NVP is outside the GP’s area 
of responsibility.  
“I do believe that when it has come so far that they are in need for treatment because the 
NVP constitutes a health risk, we refer them to the hospital.”  (GP10) 
The participants missed a “go-to medicine”, a medicine that has NVP as one of the listed 




The participants, both the pregnant women and the GPs in this study, elaborated on many issues 
related to nausea and pregnancy care. The call for help due to great distress seemed to be in 
conflict with the women’s own scepticism to use of medicines. The women were concerned about 
potential harmful effects of medicines when used during pregnancy, and therefore tried to avoid 
use. They had rather negative experiences of the meeting with health care professionals in 
relation to NVP feeling that their distress due to nausea was not taken seriously.  On the other 
hand, the GPs expressed that it was important to normalise NVP. The GPs seemed unsure about 
how to treat NVP when dietary and lifestyle interventions were insufficient. Though medicines 
were considered as the next step, the overall attitude among the GPs was to avoid medicines 
against NVP, mainly due to fear of teratogenicity. Below we discuss the strengths and limitations 
of the study design and the impact of our findings. 
Strengths and limitations 
Although this study is not generalizable beyond the participants in this setting, the data provides 
valuable insight into thoughts and attitudes among GPs and pregnant women that may be useful 
for GPs and other health care personnel in contact with this patient group. A focus group design 
was chosen as this is considered well suited to study attitudes and experiences among a group of 
people within a specific milieu (eg. health care personnel or patients) [29]. It is an efficient 
method to gather data, and it also provides some quality control through the participants own 
tendency to react to and balance out extreme views [30]. The interaction taking place within 
groups, which is considered to be the hallmark of focus groups as a method [31], was specifically 
sought to help unveil concerns and priorities which may explain behaviour patterns [27]. Due to 
slow recruitment among pregnant women, a solely strategic sampling was hindered, but still the 
sample turned out quite diverse. Though the women were in general highly educated, the age and 
parity varied among the participants. The high level of education may act as a limitation. 
However, the women without a high education did not seem restrained and were well accepted in 
the group, possibly because they had pregnancy and nausea in common.  
Our sample among GPs is relatively diverse, with varying age and gender. However, eight GPs 
had less than five years of experience. This may partly explain the participating GPs’ uncertainty 
about the choice of treatment after dietary and life style advice was given. Another possible 
limitation is that the groups of GPs belonged to the same educational group, which may result in 
withholding conflicting point of views. However, the dynamic in the groups during the sessions 
was good, and contradictory statements seemed to be well tolerated. The groups were used to 
discuss different topics during their normal educational sessions, and the participants seemed 
comfortable with the setting. Educational groups which do not have a positive group dynamic 
would probably not accept an invitation to participate in a focus group study like this.  
Due to slow recruitment, only two focus group discussions were conducted with each category of 
participants. This is an explorative study with the intention to obtain new insight into the attitudes 
behind the rationale of treatment of NVP among both the receiver of the care and the caregiver, 
not to give a full description that covers the complete picture, in accordance to Malterud [28]. 
Based on the resulting information-rich data and the broad spectrum of themes that were 
uncovered, it was considered that two groups were adequate. However, there is always the 
possibility that conducting more group discussions might have brought up other relevant themes 
than those covered by this study. 
Discussion of the findings 
The pregnant women missed a deeper understanding of and acknowledgement from health care 
personnel for how debilitating nausea can be. The women’s call for acknowledgement does not 
seem to be heard among the GPs who rather strongly agreed on the importance of normalisation 
of the symptoms of NVP. The GPs had good intentions by having this focus, as they thought it 
was important to reassure the patient that nausea is not harmful. However, it is our impression 
that the women and the GPs talk at cross purposes. The focus on normalisation was interpreted by 
the women as if the GPs did not take them seriously, especially when the GPs did not follow up 
with a proper clinical evaluation of the women’s symptoms. Due to the high prevalence of nausea 
and a busy schedule for the first pregnancy consultation, the GPs admitted that nausea was often 
just confirmed and not carefully assessed. A study of HG patients from 2000, found that a high 
level of patient satisfaction was associated with women’s perceptions that physicians believed in 
their descriptions of their symptoms [32]. Low level of belief in the patients may result in delayed 
intervention, and consequently affect the time for recovery [32], illustrating the importance of a 
good patient-GP relationship. This experienced lack of understanding of NVP among health care 
personnel was also described by Locock et al. in a study conducted in 2003-2004 illustrating 
minimal change in the situation over the last decade [6]. The well-known fact that nausea is very 
common during pregnancy and most often self-limiting, may partly explain why this complaint 
gets so little attention. Also, national and international guidelines stress the importance of 
reassuring the women that nausea is a normal part of pregnancy [25, 26, 33]. However, there are 
several studies that describe NVP’s negative impact on the women’s wellbeing resulting in poor 
quality of life, symptoms of depression, and even elective termination of an otherwise wanted 
pregnancy [8-10, 34]. Locock et al. concluded that NVP was as disruptive for everyday life as a 
chronic disease [6]. Furthermore, 35% are clinically affected of NVP and NVP accounts for 23% 
of all sick leaves during pregnancy [2, 5, 13]. About 1% develops HG [4], which in most cases 
leads to hospitalisation and its related costs for the individual and the society [5, 12]. HG has also 
been associated with giving birth to low birth weight infants [35]. The participating GPs 
demonstrated a low awareness of the negative impact of NVP.  
While the women had a clear call for help, they had a rather mixed message with respect to what 
kind of help they wanted. On one hand they criticised the GPs for not offering any prescription of 
medicines, but on the other hand, they were clearly sceptical to take medicines due to being 
pregnant.  
The women did not judge others for using medicines, but tried to the utmost to avoid use 
themselves. It was a question of how much they could bear in order to protect their child from the 
perceived harmful effects of the medicines. This is in line with previous findings [20] and is 
probably due to the previously described overestimation of risk of medicine use among pregnant 
women [22]. Referral to the Thalidomide tragedy was made by pregnant women as well as GPs. 
Though one GP stated that pharmacological management of NVP was seen to be a specialist’s 
task, not a GP’s, the other GPs agreed that pharmacological treatment was the next step. 
However, they seemed wary of treating NVP with medicines due to fear of teratogenic effects. 
This is in line with publications from UK [16], but is a paradox as there is available evidence 
supporting the safety of use during pregnancy of antiemetics [36]. The GPs expressed that 
medical treatment of NVP was mainly considered after progression of symptoms to become quite 
severe. The sceptical attitude to medicines among the women in combination with the 
normalisation and lack of evaluation of symptoms, and the reluctant attitude to treatment among 
the GPs, may prevent the question of treatment from being raised during the patient-GP 
encounter. HG is likely to be part of the continuum of nausea and vomiting during pregnancy 
[18]. The literature indicates that failure of early intervention against NVP, increases risk for 
hospitalisation due to HG [37, 38], illustrating the importance of identifying those women in need 
of treatment at an early stage. Hence, North American guidelines recommend early intervention 
to prevent progression to HG and more serious complications, including hospitalisation [17, 18]. 
Our results indicate that pregnant women requiring medical treatment against nausea would 
probably need comprehensive information and reassurance that there are treatment options which 
are considered to be effective and safe during pregnancy, before they would consider taking 
medicines. But before the participating GPs can take this position, they must obtain present 
evidence based knowledge about and confidence in available treatment options.  
  Improving quality of life during pregnancy and ability to maintain day-to-day activities for 
women with NVP should be reason enough for a GP to consider treatment. GPs meet women 
early in their pregnancy and have the opportunity to start symptom management at an early stage. 
It is recommended to communicate positive expectations regarding the outcome of a treatment to 
apply the placebo effect as a supplement to the verified treatment [39]. This contrasts the findings 
in this study where some GPs expressed little confidence in the treatment options they suggest to 
pregnant women.  
The GPs missed clearer Norwegian treatment guidelines and had a call for a medicine with NVP 
as indication. This may explain the women’s experiences of contradictory information from 
different health care personnel, and correction of prescriptions made by other physicians than the 
ones issuing it, which were described by the women who thought that this was scary and 
disturbing, rendering them even more sceptical. These findings indicate a lack of implementation 
of already existing guidelines and a need for clearer and stepwise guidelines that are easily 
accessible, to ensure consistence between health care personnel involved with pregnancy care. Of 
note, Diclegis/Diclectin, a medicine consisting of an antihistamine in combination of pyridoxine, 
with NVP as approved indication is available in Canada and USA. 
Most of the women had been on sick leave due to NVP, and had good experiences related to 
graded sick leave which made the women feel less isolated due to enabling social interaction with 
colleagues, and at the same time having time to rest to relieve the symptoms. Feelings of isolation 
have also previously been described in relation to NVP [7]. During the discussions with the GPs, 
sick leave was spontaneously mentioned when the moderator primarily addressed treatment. It 
was an impression that sick leave was an important part of the treatment regime applied by the 
GPs, probably as a consequence of a need for additional rest among women with NVP and the 
reluctance to use of medicines, with sick leave being viewed as a safe intervention from both 
parts. Sick leave often seems to be given without the concomitant prescribing of medicines that 
could give additional relief, or in some cases maybe enable the woman to work part time.  
The question of prescribing sick leave was presented as a dilemma. This demonstrates awareness 
among the GPs who are trying to build an alliance with the women, and at the same time 
acknowledging the criteria set by NAV. This is in accordance with previous findings [40].  A 
lack of an objective measure of nausea to enable documentation for NAV on what grounds the 
sick leave is being prescribed was mentioned in relation to the sick leave dilemma. The 
Pregnancy-Unique Quantification of Emesis (PUQE) scale has been translated to Norwegian and 
is included in the new national guideline for treatment of NVP [23, 41]. The PUQE scale serves 
as a tool to help objectify the women’s NVP symptoms, enables classification of degree of 
nausea (mild, moderate and severe) and is helpful in evaluating the effect of various interventions 
[41]. However, the experience of nausea, even if classified to the same degree according to 
PUQE, may deviate between different individuals. Hence, the women’s own experience should 
be acknowledged by the GPs and the women treated accordingly. 
 
Conclusion 
This Norwegian study identifies attitudes among both the participating GPs and pregnant women 
that may act as obstacles to appropriate care of women suffering from NVP. The GP’s automatic 
normalisation of symptoms and lack of assessment of the burden of NVP is interpreted as the 
main obstacle to appropriate care for women suffering from this condition. Also the women’s 
own scepticism to medical treatment while pregnant may hinder appropriate treatment when 
indicated. The pregnant women and the GPs talked at cross purposes; GPs normalisation of the 
symptoms made the women feel their distress due to NVP was trivialised by the GPs. Our results 
indicate that pregnant women requiring medical treatment against nausea would probably need 
comprehensive information and reassurance that there are safe treatment options for NVP, before 
they would consider taking medicines. However, the participating GPs showed reluctance to the 
use of medicines to treat NVP, and appeared to be insecure of the safety and the effectiveness of 
treatment.  
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